"Medicine name";"EML section";"Formulations";"Indication";"ATC codes";"Combined with";"Status"
"BCG vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against tuberculosis";"L03AX03";;"Added"
"Japanese encephalitis vaccine";"Recommendations for certain regions";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BA02, J07BA03";;"Added"
"Medicines for COVID-19";"Medicines for COVID-19";"Refer to WHO living guidelines";"COVID-19";;;"Added"
"abacavir";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Solid: 300 mg tablet (as sulfate)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF06";;"Added"
"abacavir + lamivudine";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR02";;"Added"
"abacavir + lamivudine + lopinavir + ritonavir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";;;"Removed"
"abiraterone";"Hormones and antihormones";"Oral > Solid: 250 mg; 500 mg";"Malignant neoplasms of prostate";"L02BX03";;"Added"
"acetazolamide";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Oral > Solid: 250 mg";"Primary open-angle glaucoma";"S01EC01";;"Added"
"acetic acid";"Ear, nose and throat medicines [c]";"Local > Otological > drops: 2% in alcohol";"Infectious diseases of external ear";"S02AA10";;"Added"
"acetylcysteine";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule
Oral > Liquid: 10%; 20%";"Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs";"V03AB23";;"Added"
"acetylcysteine";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 200 mg per  mL in 10 mL ampoule
Oral > Liquid: 10%; 20%";"Acute or subacute hepatic failure";"V03AB23";;"Removed"
"acetylsalicylic acid";"Antimigraine medicines > For treatment of acute attack";"Oral > Solid: 300 to 500 mg";"Migraine";"N02BA01";;"Added"
"acetylsalicylic acid";"Anti-platelet medicines";"Oral > Solid: 100 mg";"Acute myocardial infarction";"B01AC06";;"Added"
"acetylsalicylic acid";"Anti-platelet medicines";"Oral > Solid: 100 mg";"Cerebral ischaemic stroke";"B01AC06";;"Added"
"acetylsalicylic acid";"Medicines for juvenile joint diseases";"Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg";"Acute rheumatic fever without mention of heart involvement";"N02BA01";;"Added"
"acetylsalicylic acid";"Medicines for juvenile joint diseases";"Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg";"Mucocutaneous lymph node syndrome";"N02BA01";;"Added"
"acetylsalicylic acid";"Medicines for juvenile joint diseases";"Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg";"Juvenile idiopathic arthritis";"N02BA01";;"Added"
"acetylsalicylic acid";"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)";"Oral > Solid: 100 to 500 mg
Local > Rectal > Suppository: 50 to 150 mg";"Pain";"N02BA01";;"Added"
"aciclovir";"Antiherpes medicines";"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet";"Zoster";"J05AB01";;"Added"
"aciclovir";"Antiherpes medicines";"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet";"Varicella";"J05AB01";;"Added"
"aciclovir";"Antiherpes medicines";"Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet";"Herpes simplex infections";"J05AB01";;"Added"
"aciclovir";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 3% w/w";"Herpes simplex keratitis";"S01AD03";;"Added"
"aclidinium";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Chronic obstructive pulmonary disease";;;"Added"
"activated charcoal";"Antidotes and other substances used in poisonings > Non-specific";"Oral > Other: powder";"Unspecified injury, poisoning or certain other consequences of external causes";"A07BA01";;"Added"
"adalimumab";"Immunomodulators for non-malignant disease";"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL";"Axial spondyloarthritis";"L04AB04";;"Added"
"adalimumab";"Immunomodulators for non-malignant disease";"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL";"Crohn disease site";"L04AB04";;"Added"
"adalimumab";"Immunomodulators for non-malignant disease";"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL";"Rheumatoid arthritis";"L04AB04";;"Added"
"adalimumab";"Medicines for juvenile joint diseases";"Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL";"Juvenile idiopathic arthritis";"L04AB04";;"Added"
"afatinib";"Targeted therapies";;"Other specified malignant neoplasms of bronchus or lung";;;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Echinococcosis";"P02CA03";;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Ascariasis";"P02CA03";;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Enterobiasis";"P02CA03";;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Trichuriasis";"P02CA03";;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Hookworm diseases";"P02CA03";;"Added"
"albendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 400 mg (chewable, scored)
Oral > Solid > tablet: 400 mg (chewable, scored))";"Cysticercosis";"P02CA03";;"Added"
"albendazole";"Cysticidal medicines";"Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)";"Other specified echinococcosis";"P02CA03";;"Added"
"albendazole";"Cysticidal medicines";"Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)";"Cysticercosis of central nervous system";"P02CA03";;"Added"
"albendazole";"Antifilarials";"Oral > Solid > tablet: 400 mg (chewable, scored)";"Filariasis";"P02CA03";;"Added"
"alcohol based hand rub";"Disinfectants";"Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol";"Denatured alcohol";"D08AX08";;"Added"
"alcuronium";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 5 mg per  mL in 2 mL ampoule (alcuronium chloride)";"Muscle relaxants";"M03AA01";;"Removed"
"all-trans retinoic acid";"Targeted therapies";"Oral > Solid: 10 mg capsule";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01XF01";;"Added"
"allopurinol";"Medicines used to treat gout";"Oral > Solid: 100 mg";"Gout";"M04AA01";;"Added"
"allopurinol";"Supportive medicines";"Oral > Solid: 100 mg; 300 mg";"Tumour lysis syndrome";"M04AA01";;"Added"
"alteplase";"Thrombolytic medicines";"Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection";"Cerebral ischaemic stroke";"B01AD02";;"Added"
"amidotrizoate";"Diagnostic agents > Radiocontrast media";"Parenteral > General injections > unspecified: 140 to 420 mg iodine per  mL in 20 mL ampoule (as sodium or meglumine salt)";"Amidotrizoate";"V08AA01";;"Added"
"amikacin";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"amikacin";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"amikacin";"Access group antibiotics";"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)";"Acute pyelonephritis (severe)";"J01GB06";"cefotaxime";"Added"
"amikacin";"Access group antibiotics";"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)";"Acute pyelonephritis (severe)";"J01GB06";"ceftriaxone";"Added"
"amikacin";"Access group antibiotics";"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)";"Sepsis without septic shock";"J01GB06";"cloxacillin";"Added"
"amikacin";"Antituberculosis medicines";"Parenteral > General injections > unspecified: 250 mg per  mL in 2 mL vial (as sulfate)";"Multi-drug resistant Mycobacterium tuberculosis";"J01GB06";;"Added"
"amiloride";"Diuretics";"Oral > Solid: 5 mg (hydrochloride)";"Oedema";"C03DB01";;"Added"
"amiloride";"Diuretics";"Oral > Solid: 5 mg (hydrochloride)";"Ascites";"C03DB01";;"Added"
"amiodarone";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 3 ampoule (hydrochloride)
Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)";"Cardiac arrhythmia";"C01BD01";;"Added"
"amitriptyline";"Medicines for other common symptoms in palliative care";"Oral > Solid: 25 mg; 10 mg; 75 mg";"Palliative care";"N06AA09";;"Added"
"amlodipine";"Antihypertensive medicines";"Oral > Solid: 5 mg (as maleate, mesylate or besylate)";"Essential hypertension";"C08CA01";;"Added"
"amodiaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)";"Malaria due to Plasmodium falciparum";"P01BA06";;"Added"
"amodiaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)";"Malaria due to Plasmodium vivax";"P01BA06";;"Added"
"amodiaquine + sulfadoxine + pyrimethamine";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package";"Malaria";"P01BA06, P01BD51";;"Added"
"amoxicillin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection";"Sepsis without septic shock";"J01CA04";"gentamicin";"Added"
"amoxicillin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection";"Chronic obstructive pulmonary disease with acute exacerbation";"J01CA04";;"Added"
"amoxicillin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection";"Bacterial infection of unspecified site";"J01CA04";;"Removed"
"amoxicillin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection";"Infectious cystitis";"J01CA04";;"Removed"
"amoxicillin + clavulanic acid";"Access group antibiotics";"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)";"Chronic obstructive pulmonary disease with acute exacerbation";"J01CR02";;"Added"
"amoxicillin + clavulanic acid";"Access group antibiotics";"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)";"Infectious cystitis";"J01CR02";;"Added"
"amoxicillin + clavulanic acid";"Access group antibiotics";"Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
Oral > Solid: 500 mg + 125 mg tablet
Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)";"Bacterial infection of unspecified site";"J01CR02";;"Removed"
"amoxicillin + clavulanic acid";"Antituberculosis medicines";"Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)";"Multi-drug resistant Mycobacterium tuberculosis";"J01CR02";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Blastomycosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Aspergillosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Cryptococcosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Candidosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Coccidioidomycosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Histoplasmosis";"J02AA01";;"Added"
"amphotericin B";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Sporotrichosis";"J02AA01";;"Added"
"amphotericin B";"Antileishmaniasis medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)";"Visceral leishmaniasis";"J02AA01";;"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Acute malnutrition in infants, children or adolescents (complicated) [children]";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Peritonitis (mild-moderate)";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Peritonitis (severe)";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Peritoneal abscess (mild-moderate)";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Peritoneal abscess (severe)";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Sepsis without septic shock";"J01CA01";"gentamicin";"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Bacterial meningitis";"J01CA01";;"Added"
"ampicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)";"Bacterial infection of unspecified site";"J01CA01";;"Removed"
"anastrozole";"Hormones and antihormones";"Oral > Solid: 1 mg tablet";"Other specified malignant neoplasms of breast";"L02BG03";;"Added"
"anastrozole";"Hormones and antihormones";"Oral > Solid: 1 mg tablet";"Malignant neoplasms of breast";"L02BG03";;"Added"
"anidulafungin";"Antifungal medicines";;"Systemic or invasive candidosis";;;"Added"
"ansuvimab";"Medicines for Ebola virus disease";"Parenteral > General injections > IV: 400 mg powder for injection";"Ebola virus disease";"J06BD04";;"Added"
"anti-d immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IV: 250 µg in single-dose vial
Parenteral > General injections > IM: 250 µg in single-dose vial";"Maternal care for red cell antibodies";"J06BB01";;"Added"
"anti-d immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IV: 250 µg in single-dose vial
Parenteral > General injections > IM: 250 µg in single-dose vial";"Rh incompatibility reaction";"J06BB01";;"Added"
"anti-rabies immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IM: 150 IU per  mL in vial
Parenteral > Locoregional injections > Other: 150 IU per  mL in vial";"Rabies";"J06BB05";;"Added"
"anti-rabies virus monoclonal antibodies";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > Locoregional injections > Intradermal: 40 IU per  mL in 1.25 mL vial (human); 40 IU per  mL in 2.5 mL vial (human); 100 IU per  mL in 2.5 mL vial (human); 300 IU per  mL in 10 mL vial (murine); 600 IU per  mL in 1 mL vial (murine); 600 IU per  mL in 2.5 mL vial (murine); 600 IU per  mL in 5 mL vial (murine)";"Rabies";;;"Added"
"anti-tetanus immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IM: 500 IU in vial";"Tetanus";"J06BB02";;"Added"
"antirabies hyperimmune serum";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule";"Rabies";;;"Removed"
"antivenom immunoglobulin";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > General injections > IV: ";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";;;"Added"
"antivenom sera";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > General injections > IV: ";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";;;"Removed"
"apixaban";"Medicines affecting coagulation";;"Venous thromboembolism";;;"Added"
"apixaban";"Medicines affecting coagulation";;"Other specified atrial fibrillation";;;"Added"
"aprepitant";"Antiemetic medicines";"Oral > Liquid: 125 mg powder for oral suspension (in sachet)
Oral > Solid: 80 mg; 125 mg; 165 mg";"Nausea or vomiting";"A04AD12";;"Added"
"arsenic trioxide";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg per  mL concentrate for solution for infusion; 2 mg per  mL concentrate for solution for infusion";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01XX27";;"Added"
"artemether";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)";"Malaria due to Plasmodium falciparum";"P01BE02";;"Added"
"artemether";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IM: 80 mg per  mL in 1 mL ampoule (oily injection)";"Malaria due to Plasmodium vivax";"P01BE02";;"Added"
"artemether + lumefantrine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet";"Malaria due to Plasmodium falciparum";"P01BF01";;"Added"
"artemether + lumefantrine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet";"Malaria due to Plasmodium vivax";"P01BF01";;"Added"
"artesunate";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
Oral > Solid: 50 mg tablet
Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules";"Malaria due to Plasmodium falciparum";"P01BE03";;"Added"
"artesunate";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
Oral > Solid: 50 mg tablet
Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules";"Malaria due to Plasmodium vivax";"P01BE03";;"Added"
"artesunate + amodiaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet";"Malaria due to Plasmodium falciparum";"P01BF03";;"Added"
"artesunate + amodiaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet";"Malaria due to Plasmodium vivax";"P01BF03";;"Added"
"artesunate + mefloquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet";"Malaria due to Plasmodium falciparum";"P01BF02";;"Added"
"artesunate + mefloquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet";"Malaria due to Plasmodium vivax";"P01BF02";;"Added"
"artesunate + pyronaridine tetraphosphate";"Antimalarial medicines > For curative treatment";"Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules";"Malaria due to Plasmodium falciparum";"P01BF06";;"Added"
"artesunate + pyronaridine tetraphosphate";"Antimalarial medicines > For curative treatment";"Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules";"Malaria due to Plasmodium vivax";"P01BF06";;"Added"
"ascorbic acid";"Vitamins and minerals";"Oral > Solid: 50 mg";"Scurvy";"A11GA01";;"Added"
"asparaginase";"Cytotoxic medicines";"Powder for injection: 10 000 IU in vial.
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01XX02";;"Removed"
"asparaginase";"Cytotoxic medicines";"Powder for injection: 10 000 IU in vial.
Parenteral > General injections > unspecified: 10000 IU in vial powder for injection";"Lymphoid leukaemia, not elsewhere classified";"L01XX02";;"Added"
"atazanavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE08";;"Removed"
"atazanavir + ritonavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR23";;"Added"
"atenolol";"Antianginal medicines";"Oral > Solid: 50 mg; 100 mg";"Angina pectoris";"C07AB03";;"Removed"
"atenolol";"Antihypertensive medicines";"Oral > Solid: 50 mg; 100 mg
";"Essential hypertension";"C07AB03";;"Removed"
"atenolol";"Antihypertensive medicines";"Oral > Solid: 50 mg; 100 mg
";"Essential hypertension";;;"Added"
"atezolizumab";"Immunomodulators";"Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion";"Other specified malignant neoplasms of bronchus or lung";"L01XC18";;"Removed"
"atoltivimab + maftivimab + odesivimab";"Medicines for Ebola virus disease";"Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial";"Ebola virus disease";;;"Added"
"atorvastatin";"Lipid-lowering agents";;"Mixed hyperlipidaemia";;;"Added"
"atorvastatin";"Lipid-lowering agents";;"Coronary atherosclerosis";;;"Added"
"atracurium";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 10 mg per  mL (besylate)";"Muscle relaxants";"M03AC04";;"Added"
"atropine";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)";"Exposure to or harmful effects of undetermined intent of pesticides";"A03BA01";;"Added"
"atropine";"Preoperative medication and sedation for short-term procedures";"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)";"Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics";"A03BA01";;"Added"
"atropine";"Diagnostic agents > Ophthalmic medicines";;"Cycloplegic drug";;;"Added"
"atropine";"Ophthalmological preparations > Mydriatics";"Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)";"Anterior uveitis";"S01FA01";;"Added"
"axicabtagene ciloleucel";"Antineoplastics and supportive medicines";"Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.";"Diffuse large B-cell lymphomas";"L01XL03";;"Removed"
"azacitidine";"Cytotoxic medicines";"Parenteral > General injections > IV: 100 mg in vial powder for injection";"Myeloid leukaemia";"L01BC07";;"Removed"
"azathioprine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 50 mg";"Rheumatoid arthritis, serology unspecified";"L04AX01";;"Added"
"azathioprine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 50 mg";"Psoriatic arthritis";"L04AX01";;"Added"
"azathioprine";"Immunomodulators for non-malignant disease";"Oral > Solid: 50 mg
Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 10 mg per  mL
Oral > Solid > tablet: 50 mg (scored); 25 mg";"Relapsing-remitting multiple sclerosis";"L04AX01";;"Removed"
"azathioprine";"Immunomodulators for non-malignant disease";"Oral > Solid: 50 mg
Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt); 50 mg in vial powder for injection (as sodium salt)
Oral > Liquid: 10 mg per  mL
Oral > Solid > tablet: 50 mg (scored); 25 mg";"Failure or rejection of transplanted organs or tissues";"L04AX01";;"Added"
"azithromycin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 1.5% eye drops";"Trachoma";"S01AA26";;"Added"
"azithromycin";"Watch group antibiotics";"Oral > Liquid: 200 mg per 5 mL oral liquid
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule";"Gonococcal infection";"J01FA10";"ceftriaxone";"Added"
"azithromycin";"Watch group antibiotics";"Oral > Liquid: 200 mg per 5 mL oral liquid
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule";"Gonococcal infection";"J01FA10";"cefixime";"Added"
"aztreonam";"Reserve group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection";"Other specified bacterial diseases";"J01DF01";;"Removed"
"barium sulfate";"Diagnostic agents > Radiocontrast media";"Oral > Liquid: Aqueous suspension";"Barium sulfate with suspending agents";"V08BA01";;"Added"
"beclometasone";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"
Respiratory > Inhalation > aerosol: 50 µg per  dose (dipropionate); 250 µg per  dose (dipropionatae)";"Asthma";;;"Added"
"beclometasone";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"
Respiratory > Inhalation > aerosol: 50 µg per  dose (dipropionate); 250 µg per  dose (dipropionatae)";"Asthma";"R03BA01";;"Removed"
"beclometasone + formoterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"bedaquiline";"Antituberculosis medicines";"Oral > Solid: 100 mg tablet; 20 mg tablet";"Multi-drug resistant Mycobacterium tuberculosis";"J04AK05";;"Added"
"bendamustine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01AA09";;"Added"
"bendamustine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL";"Follicular lymphoma";"L01AA09";;"Added"
"benzathine benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)";"Congenital syphilis [children]";"J01CE08";;"Added"
"benzathine benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)";"Syphilis";"J01CE08";;"Added"
"benzathine benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)";"Bacterial infection of unspecified site";"J01CE08";;"Removed"
"benznidazole";"American trypanosomiasis";"Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg";"Chagas disease";"P01CA02";;"Added"
"benzoic acid + salicylic acid";"Dermatological medicines > Antifungal medicines";"Local > Topical > Cream: 6% + 3%
Local > Topical > Ointment: 6% + 3%";"Fungal infection of the skin";;;"Removed"
"benzoyl peroxide";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Cream: 5%
Local > Topical > Lotion: 5%";"Acne";"D10AE01";;"Added"
"benzyl benzoate";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 25%";"Pthiriasis";"P03AX01";;"Added"
"benzyl benzoate";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 25%";"Pediculosis corporis";"P03AX01";;"Added"
"benzyl benzoate";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 25%";"Pediculosis capitis";"P03AX01";;"Added"
"benzyl benzoate";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 25%";"Scabies";"P03AX01";;"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]";"J01CE01";"gentamicin";"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Congenital syphilis [children]";"J01CE01";;"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Syphilis";"J01CE01";;"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Acute malnutrition in infants, children or adolescents (complicated) [children]";"J01CE01";"gentamicin";"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Sepsis without septic shock";"J01CE01";"gentamicin";"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Bacterial meningitis";"J01CE01";;"Added"
"benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)";"Bacterial infection of unspecified site";"J01CE01";;"Removed"
"betamethasone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)";"Pruritus due to skin disorder";"D07AC01";;"Added"
"betamethasone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)";"Psoriasis of unspecified type";"D07AC01";;"Added"
"betamethasone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)";"Dermatitis or eczema";"D07AC01";;"Added"
"betamethasone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 0.1% (as valerate)
Local > Topical > Ointment: 0.1% (as valerate)";"Lichen planus";"D07AC01";;"Added"
"bevacizumab";"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations";"Parenteral > Locoregional injections > Intravitreal: 25 mg per  mL";"Age related macular degeneration";"S01LA08";;"Added"
"bicalutamide";"Hormones and antihormones";"Oral > Solid: 50 mg";"Malignant neoplasms of prostate";"L02BB03";;"Added"
"binimetinib";"Targeted therapies";;"Other specified melanoma of skin";;;"Removed"
"biperiden";"Medicines for parkinsonism";"Parenteral > General injections > IV: 5 mg per  mL in 1 mL ampoule (lactate)
Oral > Solid: 2 mg tablet (hydrochloride)";"Parkinson disease";"N04AA02";;"Added"
"bisacodyl";"Laxatives";;"Constipation";;;"Added"
"bisoprolol";"Antianginal medicines";"Oral > Solid: 1.25 mg; 5 mg";"Angina pectoris";"C07AB07";;"Added"
"bisoprolol";"Medicines used in heart failure";"Oral > Solid: 1.25 mg; 5 mg";"Heart failure";"C07AB07";;"Added"
"bisoprolol";"Antihypertensive medicines";"Oral > Solid: 1.25 mg; 5 mg";"Essential hypertension";"C07AB07";;"Added"
"bisoprolol";"Antiarrhythmic medicines";"Oral > Solid: 1.25 mg; 5 mg";"Cardiac arrhythmia";"C07AB07";;"Added"
"bleomycin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01DC01";;"Removed"
"bleomycin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)";"Kaposi sarcoma of unspecified primary site";"L01DC01";;"Added"
"bleomycin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)";"Hodgkin lymphoma";"L01DC01";;"Added"
"bleomycin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)";"Other specified malignant neoplasms of the ovary";"L01DC01";;"Added"
"bleomycin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 15 mg in vial (as sulfate)
Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)";"Germ cell tumour of testis";"L01DC01";;"Added"
"bortezomib";"Targeted therapies";"Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection";"Plasma cell myeloma";"L01XG01";;"Added"
"bromocriptine";"Antiseizure medicines";"Oral > Solid: 2.5 mg; 5 mg";"Parkinson disease";"N04BC01";;"Removed"
"budesonide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Respiratory > Inhalation > aerosol: 100 µg per  dose; 200 µg per  dose";"Asthma";"R03BA02";;"Added"
"budesonide";"Ear, nose and throat medicines [c]";"Local > Nasal > Spray: 100 µg per  dose";"Allergic rhinitis";"R01AD05";;"Added"
"budesonide + formoterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose";"Asthma";"R03AK07";;"Added"
"budesonide + salmeterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"bumetanide";"Medicines used in heart failure";;"Heart failure";;;"Added"
"bumetanide";"Diuretics";;"Anuria or oliguria";;;"Added"
"bumetanide";"Diuretics";;"Oedema";;;"Added"
"bupivacaine";"Local anaesthetics";"Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)";"Local anaesthetics";"N01BB01";;"Added"
"buprenorphine";"Medicines for opioid use disorders";;"Opioid dependence";;;"Added"
"bupropion";"Medicines for nicotine use disorders";"Oral > Solid: 150 mg sustained-release (hydrochloride)";"Nicotine dependence";"N06AX12";;"Added"
"c1 esterase inhibitor";"Plasma-derived medicines";"Parenteral > General injections > IV: 500 IU in vial powder for injection";"Hereditary angioedema";;;"Removed"
"cabergoline";"Antiseizure medicines";"Oral > Solid: 0.5 mg";"Parkinson disease";"N04BC06";;"Removed"
"caffeine citrate";"Medicines administered to the neonate [c]";"Parenteral > General injections > IV: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)
Oral > Liquid: 20 mg per  mL (equivalent to 10 mg caffeine base per mL)";"Apnoea of newborn";"N06BC01";;"Added"
"calamine";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Lotion: ";"Pruritus";"D02AB";;"Added"
"calcipotriol";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Cream: 50 µg per  mL (0.005%)
Local > Topical > Lotion: 50 µg per  mL (0.005%)
Local > Topical > Ointment: 50 µg per  mL (0.005%)";"Psoriasis of unspecified type";"D05AX02";;"Added"
"calcitriol";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";;"Psoriasis of unspecified type";;;"Added"
"calcium";"Vitamins and minerals";"Oral > Solid: 500 mg (elemental calcium)";"Calcium deficiency";"A12AA20";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"V03AF03";;"Removed"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Malignant neoplasm metastasis in large intestine";"V03AF03";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Malignant trophoblastic neoplasms of placenta";"V03AF03";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Burkitt lymphoma including Burkitt leukaemia";"V03AF03";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Osteosarcoma of bone and articular cartilage of unspecified sites";"V03AF03";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Malignant neoplasms of rectum";"V03AF03";;"Added"
"calcium folinate (leucovorin calcium)";"Cytotoxic medicines";"Oral > Solid: 15 mg tablet
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule
Parenteral > General injections > unspecified: 3 mg per  mL in 10 mL ampoule; 7.5 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Solid > tablet: 15 mg; 5 mg; 25 mg";"Malignant neoplasms of colon";"V03AF03";;"Added"
"calcium gluconate";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule";"Hypermagnesaemia";"A12AA03";;"Added"
"calcium gluconate";"Vitamins and minerals";"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule";"Tetany due to acute calcium deficiency";"A12AA03";;"Added"
"canagliflozin";"Oral hypoglycaemic agents";;"Type 2 diabetes mellitus";;;"Added"
"capecitabine";"Cytotoxic medicines";"Oral > Solid: 150 mg tablet; 500 mg tablet";"Malignant neoplasms of colon";"L01BC06";;"Added"
"capecitabine";"Cytotoxic medicines";"Oral > Solid: 150 mg tablet; 500 mg tablet";"Other specified malignant neoplasms of breast";"L01BC06";;"Added"
"capecitabine";"Cytotoxic medicines";"Oral > Solid: 150 mg tablet; 500 mg tablet";"Malignant neoplasm metastasis in large intestine";"L01BC06";;"Added"
"capecitabine";"Cytotoxic medicines";"Oral > Solid: 150 mg tablet; 500 mg tablet";"Malignant neoplasms of rectum";"L01BC06";;"Added"
"capreomycin";"Antituberculosis medicines";"Parenteral > General injections > IV: 1000 mg powder for injection (vial)";"Multi-drug resistant Mycobacterium tuberculosis";"J04AB30";;"Removed"
"captopril";"Medicines used in heart failure";"Oral > Solid: 25 mg";"Heart failure";"C09AA01";;"Removed"
"carbachol";"Ophthalmological preparations > Miotics and antiglaucoma medicines";;"Acute angle closure with pupillary block";;;"Added"
"carbachol";"Ophthalmological preparations > Miotics and antiglaucoma medicines";;"Ocular hypertension";;;"Added"
"carbachol";"Ophthalmological preparations > Miotics and antiglaucoma medicines";;"Primary open-angle glaucoma";;;"Added"
"carbamazepine";"Antiseizure medicines";"Oral > Liquid: 100 mg per 5 mL
Oral > Solid > tablet: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)";"Epilepsy or seizures";"N03AF01";;"Added"
"carbamazepine";"Medicines for bipolar disorders";"Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg";"Bipolar or related disorders";"N03AF01";;"Added"
"carbetocin";"Uterotonics";"Parenteral > General injections > IV: 100 µg per  mL (heat stable)";"Postpartum haemorrhage";"H01BB03";;"Added"
"carbimazole";"Thyroid hormones and antithyroid medicines";;"Thyrotoxicosis";;;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Other specified gliomas of brain";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Other specified carcinomas of ovary";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Retinoblastoma";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Other specified malignant neoplasms of bronchus or lung";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Malignant neoplasms of nasopharynx";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Malignant neoplasms of kidney, except renal pelvis";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Malignant neoplasms of breast";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Malignant neoplasms of lip, oral cavity or pharynx";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Malignant neoplasms of cervix uteri";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Other specified malignant neoplasms of the ovary";"L01XA02";;"Added"
"carboplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL";"Germ cell tumour of testis";"L01XA02";;"Added"
"carvedilol";"Antianginal medicines";;"Angina pectoris";;;"Added"
"carvedilol";"Medicines used in heart failure";;"Heart failure";;;"Added"
"carvedilol";"Antihypertensive medicines";;"Essential hypertension";;;"Added"
"carvedilol";"Antiarrhythmic medicines";;"Cardiac arrhythmia";;;"Added"
"caspofungin";"Antifungal medicines";;"Systemic or invasive candidosis";;;"Added"
"cefalexin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate)
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)";"Chronic obstructive pulmonary disease with acute exacerbation";"J01DB01";;"Added"
"cefalexin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
Oral > Solid: 250 mg (as monohydrate)
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)";"Bacterial infection of unspecified site";"J01DB01";;"Removed"
"cefazolin";"Access group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection";"Other specified prophylactic measures";"J01DB04";"metronidazole";"Added"
"cefazolin";"Access group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection";"Other specified prophylactic measures";"J01DB04";;"Added"
"cefazolin";"Access group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection";"Bacterial infection of joint";"J01DB04";;"Added"
"cefazolin";"Access group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection";"Osteomyelitis or osteitis";"J01DB04";;"Added"
"cefazolin";"Access group antibiotics";"Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection";"Surgical site infection";"J01DB04";;"Removed"
"cefepime";"Watch group antibiotics";"Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection";"Other specified bacterial diseases";"J01DE01";;"Removed"
"cefixime";"Watch group antibiotics";"Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)";"Infectious gastroenteritis or colitis without specification of infectious agent";"J01DD08";;"Added"
"cefixime";"Watch group antibiotics";"Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)";"Gonococcal infection";"J01DD08";"azithromycin";"Added"
"cefotaxime";"Watch group antibiotics";"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)";"Bacterial infection of unspecified site";"J01DD01";;"Removed"
"ceftaroline";"Reserve group antibiotics";"Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection";"Other specified bacterial diseases";"J01DI02";;"Removed"
"ceftazidime";"Watch group antibiotics";"Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection";"Endophthalmitis";"J01DD02";"vancomycin";"Added"
"ceftazidime";"Watch group antibiotics";"Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection";"Pseudomonas aeruginosa resistant to other antibiotic";"J01DD02";;"Added"
"ceftazidime + avibactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection";"Carbapenem-resistant Pseudomonas aeruginosa";"J01DD52";;"Added"
"ceftazidime + avibactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection";"Carbapenem resistant Enterobacterales";"J01DD52";;"Added"
"ceftolozane + tazobactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 1 g + 0.5 g powder for injection";"Carbapenem-resistant Pseudomonas aeruginosa";"J01DI54";;"Added"
"ceftriaxone";"Watch group antibiotics";"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)";"Necrotising fasciitis";"J01DD04";"metronidazole";"Added"
"ceftriaxone";"Watch group antibiotics";"Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)";"Bacterial infection of unspecified site";"J01DD04";;"Removed"
"cefuroxime";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection";"Other specified prophylactic measures";"J01DC02";;"Added"
"certolizumab pegol";"Immunomodulators for non-malignant disease";;"Axial spondyloarthritis";;;"Added"
"certolizumab pegol";"Immunomodulators for non-malignant disease";;"Crohn disease site";;;"Added"
"certolizumab pegol";"Immunomodulators for non-malignant disease";;"Rheumatoid arthritis";;;"Added"
"certolizumab pegol";"Medicines for juvenile joint diseases";;"Juvenile idiopathic arthritis";;;"Added"
"cetirizine";"Antiallergics and medicines used in anaphylaxis";;"Allergic or hypersensitivity conditions of unspecified type";;;"Added"
"chlorambucil";"Cytotoxic medicines";"Oral > Solid: 2 mg tablet";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01AA02";;"Removed"
"chlorambucil";"Cytotoxic medicines";"Oral > Solid: 2 mg tablet";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01AA02";;"Added"
"chloramphenicol";"Access group antibiotics";"Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
Oral > Liquid: 150 mg per 5 mL (as palmitate)
Oral > Solid: 250 mg capsule";"Bacterial infection of unspecified site";"J01BA01";;"Removed"
"chlorhexidine";"Medicines administered to the neonate [c]";"Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)";"Omphalitis of newborn";"D08AC02";;"Added"
"chlorhexidine";"Antiseptics";"Local > Topical > Solution: 5% (digluconate) for dilution";"Chlorhexidine";"D08AC02";;"Added"
"chlorine base compound";"Disinfectants";"Local > Topical > Powder: 0.1% available chlorine for solution
Local > Topical > Liquid: 0.1% available chlorine for solution
Local > Topical > Solid: 0.1% available chlorine for solution";"Disinfectant, not elsewhere classified";;;"Added"
"chloroquine";"Antimalarial medicines > For chemoprevention";"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium falciparum";"P01BA01";;"Removed"
"chloroquine";"Antimalarial medicines > For chemoprevention";"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium vivax";"P01BA01";;"Added"
"chloroquine";"Antimalarial medicines > For chemoprevention";"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium ovale";"P01BA01";;"Added"
"chloroquine";"Antimalarial medicines > For chemoprevention";"Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium malariae";"P01BA01";;"Added"
"chloroquine";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium falciparum";"P01BA01";;"Removed"
"chloroquine";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IV: 40 mg per  mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)";"Malaria due to Plasmodium vivax";"P01BA01";;"Added"
"chloroquine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)";"Rheumatoid arthritis";"P01BA01";;"Added"
"chlorothiazide";"Antihypertensive medicines";;"Essential hypertension";;;"Added"
"chlorothiazide";"Medicines used in heart failure";;"Heart failure";;;"Added"
"chloroxylenol";"Disinfectants";"Local > Topical > Solution: 4.8%";"Phenol disinfectant, not elsewhere classified";"D08AE05";;"Added"
"chlortalidone";"Antihypertensive medicines";;"Essential hypertension";;;"Added"
"chlortalidone";"Medicines used in heart failure";;"Heart failure";;;"Added"
"chlortetracycline";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"chlortetracycline";"Ophthalmological preparations > Anti-infective agents";;"Infectious keratitis";;;"Added"
"chlortetracycline";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"chlortetracycline";"Ophthalmological preparations > Anti-infective agents";;"Trachoma";;;"Added"
"cholera vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against cholera alone";"J07AE01";;"Added"
"ciclesonide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"ciclosporin";"Immunomodulators for non-malignant disease";"Parenteral > General injections > IV: 50 mg per  mL in 1 mL ampoule concentrate for injection
Oral > Liquid: 100 mg per  mL
Oral > Solid > capsule: 25 mg";"Failure or rejection of transplanted organs or tissues";"L04AD01";;"Added"
"cimetidine";"Antiulcer medicines";"Oral > Solid: 200 mg
Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule";"Peptic ulcer, site unspecified";"A02BA01";;"Removed"
"cimetidine";"Antiulcer medicines";"Oral > Solid: 200 mg
Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule";"Gastro-oesophageal reflux disease";"A02BA01";;"Removed"
"ciprofloxacin";"Watch group antibiotics";"Parenteral > General injections > IV: 2 mg per  mL (as hyclate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)
Oral > Solid: 250 mg (as hydrochloride)
Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)";"Inflammatory and other diseases of prostate (mild to moderate)";"J01MA02";;"Added"
"ciprofloxacin";"Watch group antibiotics";"Parenteral > General injections > IV: 2 mg per  mL (as hyclate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)
Oral > Solid: 250 mg (as hydrochloride)
Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)";"Bacterial infection of unspecified site";"J01MA02";;"Removed"
"ciprofloxacin";"Ear, nose and throat medicines [c]";"Local > Otological > drops: 0.3% (as hydrochloride)";"Infectious diseases of external ear";"S02AA15";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01XA01";;"Removed"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Other specified gliomas of brain";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Other specified malignant neoplasms of the ovary";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Other specified malignant neoplasms of bronchus or lung";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Malignant neoplasms of nasopharynx";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Germ cell tumour of testis";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Malignant neoplasms of lip, oral cavity or pharynx";"L01XA01";;"Added"
"cisplatin";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL";"Malignant neoplasms of cervix uteri";"L01XA01";;"Added"
"cladribine";"Medicines for multiple sclerosis";"Oral > Solid > tablet: 10 mg";"Multiple sclerosis";"L04AA40";;"Added"
"cladribine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg per  mL in 10 mL vial; 2 mg per  mL in 5 mL vial";"Langerhans cell histiocytosis";"L01BB04";;"Removed"
"clindamycin";"Access group antibiotics";"Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
Oral > Solid: 150 mg (as hydrochloride) capsule
Parenteral > General injections > unspecified: 150 mg per  mL (as phosphate) injection";"Bacterial infection of unspecified site";"J01FF01";;"Removed"
"clofazimine";"Antituberculosis medicines";"Oral > Solid: 100 mg; 50 mg";"Multi-drug resistant Mycobacterium tuberculosis";"J04BA01";;"Added"
"clofazimine";"Antileprosy medicines";"Oral > Solid: 100 mg; 50 mg";"Leprosy";"J04BA01";;"Added"
"clomifene";"Ovulation inducers";"Oral > Solid: 50 mg (citrate)";"Female infertility without specification whether primary or secondary";"G03GB02";;"Added"
"clomipramine";"Medicines for obsessive compulsive disorders";"Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)";"Obsessive-compulsive disorder";"N06AA04";;"Added"
"clonazepam";"Antiseizure medicines";"Oral > Solid: 500 µg";"Generalised myoclonic seizure";"N03AE01";;"Removed"
"clopidogrel";"Anti-platelet medicines";"Oral > Solid: 75 mg; 300 mg";"Acute ischaemic heart disease";"B01AC04";;"Added"
"clopidogrel";"Anti-platelet medicines";"Oral > Solid: 75 mg; 300 mg";"Presence of coronary angioplasty implant or graft";"B01AC04";;"Added"
"clotrimazole";"Antifungal medicines";"Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet";"Vulvovaginal candidosis";"G01AF02";;"Added"
"cloxacillin";"Access group antibiotics";"Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection";"Bacterial infection of unspecified site";"J01CF02";;"Removed"
"clozapine";"Medicines for psychotic disorders";"Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg";"Schizophrenia or other primary psychotic disorders";"N05AH02";;"Added"
"coal tar";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 5%";"Psoriasis of unspecified type";"D05AA";;"Added"
"cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR09";;"Removed"
"cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR18";;"Removed"
"cobimetinib";"Targeted therapies";;"Other specified melanoma of skin";;;"Removed"
"codeine";"Opioid analgesics";"Oral > Solid: 30 mg tablet (codeine phosphate)";"Pain";;;"Added"
"codeine";"Antitussives";"Oral > Solid: 10 mg tablet (codeine phosphate)";"Cough";"R05DA04";;"Removed"
"codeine";"Medicines for diarrhoea";"Oral > Solid: 30 mg tablet (codeine phosphate)";"Diarrhoea";;;"Removed"
"colchicine";"Medicines used to treat gout";"Oral > Solid: 0.5 mg";"Gout";"M04AC01";;"Removed"
"colecalciferol";"Vitamins and minerals";"Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
";"Calcium deficiency";"A11CC05";;"Added"
"colecalciferol";"Vitamins and minerals";"Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
";"Vitamin D deficiency";"A11CC05";;"Added"
"colecalciferol";"Vitamins and minerals";"Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
";"Vitamin D deficiency";;;"Added"
"colecalciferol";"Vitamins and minerals";"Oral > Liquid: 400 IU per  mL
Oral > Solid: 400 IU; 1000 IU
";"Calcium deficiency";;;"Added"
"colistin (injection)";"Reserve group antibiotics";"Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)";"Other specified bacterial diseases";"J01XB01";;"Removed"
"compound sodium lactate solution";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: injectable solution";"Other specified disorders of fluid, electrolyte or acid-base balance";;;"Added"
"compound sodium lactate solution";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: injectable solution";"Hypovolaemic shock";;;"Added"
"condoms";"Barrier methods";"-";"Contact with health services for contraceptive management";;;"Added"
"copper-containing intrauterine device";"Intrauterine devices";"-";"Contact with health services for insertion of contraceptive device";"G02BA02";;"Added"
"crizotinib";"Targeted therapies";"Oral > Solid: 200 mg; 250 mg
Oral > Solid > capsule: 200 mg; 250 mg";"Other specified malignant neoplasms of bronchus or lung";"L01ED01";;"Removed"
"crizotinib";"Targeted therapies";"Oral > Solid: 200 mg; 250 mg
Oral > Solid > capsule: 200 mg; 250 mg";"Anaplastic large cell lymphoma, ALK-positive";"L01ED01";;"Removed"
"cyanocobalamin";"Antianaemia medicines";".";"Anaemias or other erythrocyte disorders";"B03BA01";;"Removed"
"cyclizine";"Medicines for other common symptoms in palliative care";"Oral > Solid: 50 mg tablet
Parenteral > General injections > unspecified: 50 mg per  mL";"Palliative care";"R06AE03";;"Added"
"cyclopentolate";"Diagnostic agents > Ophthalmic medicines";;"Cycloplegic drug";;;"Added"
"cyclopentolate";"Ophthalmological preparations > Mydriatics";;"Anterior uveitis";;;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01AA01";;"Removed"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Burkitt lymphoma including Burkitt leukaemia";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Malignant neoplasms of breast";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Lymphoid leukaemia, not elsewhere classified";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Diffuse large B-cell lymphomas";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Plasma cell myeloma";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Other specified gliomas of brain";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Other specified malignant neoplasms of breast";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Malignant trophoblastic neoplasms of placenta";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Follicular lymphoma";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Malignant neoplasms of kidney, except renal pelvis";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Rhabdomyosarcoma primary site";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Hodgkin lymphoma";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Anaplastic large cell lymphoma, ALK-negative";"L01AA01";;"Added"
"cyclophosphamide";"Cytotoxic medicines";"Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg; 50 mg tablet";"Anaplastic large cell lymphoma, ALK-positive";"L01AA01";;"Added"
"cycloserine";"Antituberculosis medicines";"Oral > Solid: 250 mg; 125 mg";"Multi-drug resistant Mycobacterium tuberculosis";"J04AB01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01BC01";;"Removed"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Lymphoid leukaemia, not elsewhere classified";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Myeloid leukaemia";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Burkitt lymphoma including Burkitt leukaemia";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Anaplastic large cell lymphoma, ALK-negative";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Anaplastic large cell lymphoma, ALK-positive";"L01BC01";;"Added"
"cytarabine";"Cytotoxic medicines";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per  mL in vial";"Langerhans cell histiocytosis";"L01BC01";;"Added"
"dabigatran";"Medicines affecting coagulation";"Oral > Solid: 110 mg; 150 mg";"Venous thromboembolism";"B01AE07";;"Added"
"dabigatran";"Medicines affecting coagulation";"Oral > Solid: 110 mg; 150 mg";"Other specified atrial fibrillation";"B01AE07";;"Added"
"dabrafenib";"Targeted therapies";"Oral > Solid: 50 mg; 75 mg";"Other specified melanoma of skin";"L01EC02";;"Removed"
"dacarbazine";"Cytotoxic medicines";"Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection";"Hodgkin lymphoma";"L01AX04";;"Added"
"daclatasvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)";"Chronic hepatitis C";"J05AP07";;"Added"
"daclatasvir + sofosbuvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid: 60 mg + 400 mg";"Chronic hepatitis C";"J05AP07, J05AP08";;"Added"
"dactinomycin";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 µg in vial powder for injection";"Malignant trophoblastic neoplasms of placenta";"L01DA01";;"Added"
"dactinomycin";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 µg in vial powder for injection";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01DA01";;"Removed"
"dactinomycin";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 µg in vial powder for injection";"Malignant neoplasms of kidney, except renal pelvis";"L01DA01";;"Added"
"dactinomycin";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 µg in vial powder for injection";"Rhabdomyosarcoma primary site";"L01DA01";;"Added"
"dactinomycin";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 µg in vial powder for injection";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01DA01";;"Added"
"dalteparin";"Medicines affecting coagulation";;"Acute ischaemic heart disease";;;"Added"
"dalteparin";"Medicines affecting coagulation";;"Venous thromboembolism";;;"Added"
"dapagliflozin";"Oral hypoglycaemic agents";;"Type 2 diabetes mellitus";;;"Added"
"dapsone";"Antileprosy medicines";"Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet";"Leprosy";"J04BA02";;"Added"
"daptomycin";"Reserve group antibiotics";"Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection";"Other specified bacterial diseases";"J01XX09";;"Removed"
"daratumumab";"Immunomodulators";"Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL";"Plasma cell myeloma";"L01FC01";;"Removed"
"darbepoetin alfa";"Antianaemia medicines";;"Anaemia due to chronic disease";;;"Added"
"darunavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE10";;"Added"
"dasabuvir";"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations";"Oral > Solid: 250 mg tablet";"Chronic hepatitis C";"J05AX16";;"Removed"
"dasatinib";"Targeted therapies";"Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet";"Chronic myeloid leukaemia, not elsewhere classified";"L01EA02";;"Added"
"daunorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)";"Lymphoid leukaemia, not elsewhere classified";"L01DB02";;"Added"
"daunorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)";"Myeloid leukaemia";"L01DB02";;"Added"
"daunorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per  mL in vial (as hydrochloride); 5 mg per  mL in vial (as hydrochloride)";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01DB02";;"Added"
"deferoxamine";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)";"Harmful effects of drugs, medicaments or biological substances, not elsewhere classified";"V03AC01";;"Added"
"delafloxacin";"Watch group antibiotics";"Parenteral > General injections > IV: 300 mg lyophilized powder for injection
Oral > Solid: 450 mg";"Methicillin resistant Staphylococcus aureus";"J01MA23";;"Removed"
"delamanid";"Antituberculosis medicines";"Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)";"Multi-drug resistant Mycobacterium tuberculosis";"J04AK06";;"Added"
"dengue vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BX04";;"Added"
"desmopressin";"Medicines affecting coagulation";"Parenteral > General injections > IV: 4 µg per  mL in 1 mL ampoule (acetate)
Local > Nasal > Spray: 10 µg per  dose (acetate)";"Haemophilia A";"H01BA02";;"Added"
"desmopressin";"Medicines affecting coagulation";"Parenteral > General injections > IV: 4 µg per  mL in 1 mL ampoule (acetate)
Local > Nasal > Spray: 10 µg per  dose (acetate)";"Von Willebrand disease";"H01BA02";;"Added"
"dexamethasone";"Other medicines administered to the mother";"Parenteral > General injections > unspecified: 4 mg per  mL (dexamethasone phosphate (as sodium))";"Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy";"H02AB02";;"Added"
"dexamethasone";"Hormones and antihormones";"Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg";"Plasma cell myeloma";"L01AA01";;"Added"
"dexamethasone";"Hormones and antihormones";"Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg";"Lymphoid leukaemia, not elsewhere classified";"H02AB02";;"Added"
"dexamethasone";"Hormones and antihormones";"Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg";"Burkitt lymphoma including Burkitt leukaemia";"H02AB02";;"Added"
"dexamethasone";"Hormones and antihormones";"Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg";"Anaplastic large cell lymphoma, ALK-negative";"H02AB02";;"Added"
"dexamethasone";"Hormones and antihormones";"Oral > Solid: 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg";"Anaplastic large cell lymphoma, ALK-positive";"H02AB02";;"Added"
"dexamethasone";"Antiallergics and medicines used in anaphylaxis";"Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)";"Allergic or hypersensitivity conditions of unspecified type";"H02AB02";;"Added"
"dexamethasone";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 2 mg; 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)";"Palliative care";"C05AA09";;"Added"
"dexamethasone";"Antiemetic medicines";"Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
Parenteral > General injections > unspecified: 4 mg per  mL in 1 mL ampoule (as disodium phosphate salt)";"Nausea or vomiting";"H02AB02";;"Added"
"dextran 40";"Plasma substitutes";".";"Hypovolaemia";"B05AA05";;"Removed"
"dextran 70";"Plasma substitutes";"Parenteral > General injections > IV: 6% injectable solution";"Hypovolaemia";"B05AA05";;"Added"
"diaphragms";"Barrier methods";"-";"Contact with health services for contraceptive management";;;"Added"
"diazepam";"Antiseizure medicines";"
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube";"Status epilepticus";;;"Added"
"diazepam";"Antiseizure medicines";"
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube";"Status epilepticus";"N05BA01";;"Added"
"diazepam";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 2 mg per 5 mL
Oral > Solid: 5 mg; 10 mg
Local > Rectal > Gel: 5 mg per  mL in 0.5 mL rectal delivery system; 5 mg per  mL in 2 mL rectal delivery system; 5 mg per  mL in 4 mL rectal delivery system
Local > Rectal > Solution: 2 mg per  mL in 1.25 mL rectal tube; 2 mg per  mL in 2.5 mL rectal tube; 4 mg per  mL in 2.5 mL rectal tube
Parenteral > General injections > unspecified: 5 mg per  mL";"Palliative care";"N05BA01";;"Added"
"diazoxide";"Medicines for hypoglycaemia";"Oral > Liquid: 50 mg per  mL
Oral > Solid: 50 mg";"Persistent hyperinsulinaemic hypoglycaemia of infancy";"V03AH01";;"Added"
"didanosine";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF02";;"Removed"
"diethylcarbamazine";"Antifilarials";"Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)";"Lymphatic filariasis";"P02CB02";;"Added"
"digitoxin";"Medicines used in heart failure";"Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
Oral > Solid: 50 µg; 100 µg";"Heart failure";"C01AA04";;"Removed"
"digoxin";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 250 µg per  mL in 2 mL ampoule
Oral > Liquid: 50 µg per  mL
Oral > Solid: 62.5 µg; 250 µg";"Cardiac arrhythmia";"C01AA05";;"Added"
"digoxin";"Medicines used in heart failure";"Parenteral > General injections > IV: 250 µg per  mL in 2 mL ampoule; 100 µg per  mL in 1 mL ampoule
Oral > Liquid: 50 µg per  mL
Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg";"Heart failure";"C01AA05";;"Added"
"dihydroartemisinin + piperaquine phosphate";"Antimalarial medicines > For curative treatment";"Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet";"Malaria due to Plasmodium falciparum";"P01BF05";;"Added"
"dihydroartemisinin + piperaquine phosphate";"Antimalarial medicines > For curative treatment";"Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet";"Malaria due to Plasmodium vivax";"P01BF05";;"Added"
"dihydroergocryptine mesylate";"Antiseizure medicines";"Oral > Solid: ";"Parkinson disease";"N04BC03";;"Removed"
"diloxanide";"Antiamoebic and antigiardiasis medicines";"Oral > Solid: 500 mg (furoate)";"Amoebiasis";"P01AC01";;"Added"
"dimercaprol";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IM: 50 mg per  mL in 2 mL ampoule";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB09";;"Added"
"diphtheria antitoxin";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial";"Need for immunization against diphtheria alone";"J06AA01";;"Added"
"diphtheria vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against diphtheria alone";"J07AF01";;"Added"
"diphtheria-pertussis-tetanus vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against diphtheria-tetanus-pertussis, combined";"J07AJ52";;"Removed"
"diphtheria-tetanus vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against combinations of infectious diseases";"J07AM51";;"Removed"
"docetaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL";"Other specified malignant neoplasms of breast";"L01CD02";;"Added"
"docetaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL";"Malignant neoplasms of breast";"L01CD02";;"Added"
"docetaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL";"Malignant neoplasms of prostate";"L01CD02";;"Added"
"docetaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL; 40 mg per  mL";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01CD02";;"Removed"
"docusate sodium";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 50 mg per 5 mL oral liquid
Oral > Solid: 100 mg capsule";"Palliative care";"A06AA02";;"Added"
"dolasetron";"Medicines for other common symptoms in palliative care";;"Palliative care";;;"Added"
"dolasetron";"Antiemetic medicines";;"Nausea or vomiting";;;"Added"
"dolutegravir";"Antiretrovirals > Integrase inhibitors";"Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AJ03";;"Added"
"dolutegravir + lamivudine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR27";;"Added"
"donepezil";"Medicines for diseases of the nervous system";"Oral > Liquid: 1 mg per  mL (hydrochloride)
Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible)";"Dementia due to Alzheimer disease";"N06DA02";;"Removed"
"dopamine";"Medicines used in heart failure";"Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)";"Heart failure";"C01CA04";;"Added"
"dopamine";"Medicines used in heart failure";"Parenteral > General injections > IV: 40 mg per  mL in 5 mL vial (hydrochloride)";"Cardiogenic shock";"C01CA04";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01DB01";;"Removed"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Rhabdomyosarcoma primary site";"L01DB01";;"Removed"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Follicular lymphoma";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Burkitt lymphoma including Burkitt leukaemia";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Malignant neoplasms of breast";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Lymphoid leukaemia, not elsewhere classified";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Other specified malignant neoplasms of breast";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Diffuse large B-cell lymphomas";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Plasma cell myeloma";"L01AA01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Malignant neoplasms of kidney, except renal pelvis";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Kaposi sarcoma of unspecified primary site";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Hodgkin lymphoma";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Anaplastic large cell lymphoma, ALK-negative";"L01DB01";;"Added"
"doxorubicin";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per  mL in 5 mL vial (hydrochloride); 2 mg per  mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)";"Anaplastic large cell lymphoma, ALK-positive";"L01DB01";;"Added"
"doxycycline";"Access group antibiotics";"Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)";"Chlamydia trachomatis";"J01AA02";;"Added"
"doxycycline";"Access group antibiotics";"Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)";"Chronic obstructive pulmonary disease with acute exacerbation";"J01AA02";;"Added"
"doxycycline";"Access group antibiotics";"Oral > Solid: 100 mg (as hyclate)
Parenteral > General injections > unspecified: 100 mg in vial powder for injection
Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)";"Bacterial infection of unspecified site";"J01AA02";;"Removed"
"doxycycline";"Antimalarial medicines > For curative treatment";"Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)";"Malaria due to Plasmodium falciparum";"J01AA02";;"Added"
"doxycycline";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 100 mg (hydrochloride or hyclate)";"Malaria due to Plasmodium falciparum";"J01AA02";;"Added"
"edoxaban";"Medicines affecting coagulation";;"Venous thromboembolism";;;"Added"
"edoxaban";"Medicines affecting coagulation";;"Other specified atrial fibrillation";;;"Added"
"efavirenz";"Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors";"Oral > Solid: 600 mg tablet";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AG03";;"Added"
"efavirenz + emtricitabine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR06";;"Added"
"efavirenz + lamivudine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR11";;"Added"
"efavirenz + lamivudine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";;;"Added"
"eflornithine";"Medicines for the treatment of 2nd stage African trypanosomiasis";"Parenteral > General injections > IV: 200 mg per  mL in 50 mL bottle (hydrochloride)";"African trypanosomiasis";"P01CX03";;"Added"
"elbasvir + grazoprevir";"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations";"Oral > Solid: 50 mg + 100 mg";"Chronic hepatitis C";"J05AP54";;"Removed"
"empagliflozin";"Oral hypoglycaemic agents";"Oral > Solid: 10 mg; 25 mg";"Type 2 diabetes mellitus";"A10BK03";;"Added"
"emtricitabine";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 200 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF09";;"Removed"
"emtricitabine + rilpivirine + tenofovir alafenamide";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 200 mg + 25 mg + 25 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR19";;"Removed"
"emtricitabine + rilpivirine + tenofovir disoproxil fumarate";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR08";;"Removed"
"emtricitabine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR03";;"Added"
"emtricitabine + tenofovir";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)";"Contact with or exposure to human immunodeficiency virus";"J05AR03";;"Added"
"emtricitabine + tenofovir alafenamide";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR17";;"Removed"
"enalapril";"Antihypertensive medicines";"Oral > Liquid: 1 mg per  mL (as hydrogen maleate)
Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)";"Essential hypertension";"C09AA02";;"Added"
"enalapril";"Medicines used in heart failure";"Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)";"Heart failure";"C09AA02";;"Added"
"encorafenib";"Targeted therapies";;"Other specified melanoma of skin";;;"Removed"
"enoxaparin";"Medicines affecting coagulation";"Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule";"Acute ischaemic heart disease";"B01AB05";;"Added"
"enoxaparin";"Medicines affecting coagulation";"Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule";"Venous thromboembolism";"B01AB05";;"Added"
"entecavir";"Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Liquid: 0.05 mg per  mL
Oral > Solid: 0.5 mg; 1 mg";"Chronic hepatitis B";"J05AF10";;"Added"
"enzalutamide";"Hormones and antihormones";"
Oral > Solid: 40 mg";"Malignant neoplasms of prostate";;;"Added"
"enzalutamide";"Hormones and antihormones";"
Oral > Solid: 40 mg";"Malignant neoplasms of prostate";"L02BB04";;"Removed"
"ephedrine";"Local anaesthetics";"Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per  mL in 1 mL ampoule (ephedrine hydrochloride)";"Cardiac complications of anaesthesia during labour or delivery";"C01CA26";;"Added"
"epinephrine";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 100 µg per  mL in 10 mL ampoule (as acid tartrate or hydrochloride)";"Cardiac arrest";"C01CA24";;"Added"
"epinephrine";"Ophthalmological preparations > Mydriatics";"Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)";"Primary open-angle glaucoma";"S01EA01";;"Added"
"epinephrine";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)";"Asthma";"C01CA24";;"Added"
"epinephrine";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Parenteral > General injections > unspecified: 1 mg per  mL in ampoule (as hydrochloride or hydrogen tartrate)";"Chronic obstructive pulmonary disease";"R03AA01";;"Added"
"epinephrine";"Antiallergics and medicines used in anaphylaxis";"Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)";"Anaphylaxis";"C01CA24";;"Added"
"epoetin alfa";"Antianaemia medicines";;"Anaemia due to chronic disease";;;"Added"
"epoetin beta";"Antianaemia medicines";;"Anaemia due to chronic disease";;;"Added"
"epoetin theta";"Antianaemia medicines";;"Anaemia due to chronic disease";;;"Added"
"equine rabies immunoglobulin";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > Locoregional injections > Intradermal: 150 IU per  mL in vial; 200 IU per  mL in vial; 300 IU per  mL in vial; 400 IU per  mL in vial";"Rabies";"J06BB05";;"Added"
"eravacycline";"Reserve group antibiotics";"Parenteral > General injections > IV: 50 mg lyophilized powder for injection";"Carbapenem resistant Enterobacterales";"J01AA13";;"Removed"
"ergocalciferol";"Vitamins and minerals";"
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)";"Calcium deficiency";;;"Added"
"ergocalciferol";"Vitamins and minerals";"
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)";"Vitamin D deficiency";;;"Added"
"ergocalciferol";"Vitamins and minerals";"
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)";"Vitamin D deficiency";"A11CC01";;"Added"
"ergocalciferol";"Vitamins and minerals";"
Oral > Liquid: 250 µg per  mL (10 000 IU per mL)
Oral > Solid: 1.25 mg (50 000 IU)";"Calcium deficiency";"A11CC01";;"Added"
"ergometrine";"Uterotonics";"Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)";"Postpartum haemorrhage";"G02AB03";;"Added"
"erlotinib";"Targeted therapies";"Oral > Solid: 100 mg; 150 mg";"Other specified malignant neoplasms of bronchus or lung";"L01EB02";;"Added"
"erythromycin";"Watch group antibiotics";"Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
Oral > Solid: 250 mg (as stearate or ethylsuccinate)";"Bacterial infection of unspecified site";"J01FA01";;"Removed"
"erythromycin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 0.5%";"Chlamydial conjunctivitis";"S01AA17";;"Added"
"erythromycin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 0.5%";"Gonococcal infection of eye";"S01AA17";;"Added"
"erythropoiesis-stimulating agents";"Antianaemia medicines";"Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe";"Anaemia due to chronic disease";"B03XA03, B03XA01, B03XA02";;"Added"
"estradiol cypionate + medroxyprogesterone acetate";"Injectable hormonal contraceptives";"Parenteral > General injections > IM: 5 mg + 25 mg";"Contact with health services for reasons associated with reproduction";"G03AA08";;"Added"
"etanercept";"Immunomodulators for non-malignant disease";;"Axial spondyloarthritis";;;"Added"
"etanercept";"Immunomodulators for non-malignant disease";;"Crohn disease site";;;"Added"
"etanercept";"Immunomodulators for non-malignant disease";;"Rheumatoid arthritis";;;"Added"
"etanercept";"Medicines for juvenile joint diseases";;"Juvenile idiopathic arthritis";;;"Added"
"ethambutol";"Antituberculosis medicines";"Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)";"Other specified tuberculosis";"J04AK02";;"Removed"
"ethambutol";"Antituberculosis medicines";"Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)";"Tuberculosis";"J04AK02";;"Added"
"ethambutol + isoniazid";"Antituberculosis medicines";"Oral > Solid: 400 mg + 150 mg tablet";"Tuberculosis";"J04AM03";;"Removed"
"ethambutol + isoniazid + pyrazinamide + rifampicin";"Antituberculosis medicines";"Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet";"Tuberculosis";"J04AM06";;"Added"
"ethambutol + isoniazid + rifampicin";"Antituberculosis medicines";"Oral > Solid: 275 mg + 75 mg + 150 mg tablet";"Tuberculosis";"J04AK02, J04AC01, J04AB02";;"Added"
"ethanol";"Antiseptics";"Local > Topical > Solution: 70% (denatured)";"Denatured alcohol";"D08AX08";;"Added"
"ether";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation > solution: ";"Anaesthetics and therapeutic gases";"N01AA01";;"Removed"
"ethinylestradiol + etonogestrel";"Intravaginal contraceptives";"Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg";"Contact with health services for contraceptive management";"G02BB01";;"Added"
"ethinylestradiol + levonorgestrel";"Oral hormonal contraceptives";"Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg";"Contact with health services for postcoital contraception";"G03AA07";;"Removed"
"ethinylestradiol + levonorgestrel";"Oral hormonal contraceptives";"Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg";"Contact with health services for contraceptive management";"G03AA07";;"Added"
"ethinylestradiol + norethisterone";"Oral hormonal contraceptives";"Oral > Solid: 35 µg + 1 mg";"Contact with health services for contraceptive management";"G03AA05";;"Added"
"ethionamide";"Antituberculosis medicines";"Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)";"Multi-drug resistant Mycobacterium tuberculosis";"J04AD03";;"Added"
"ethionamide";"Antituberculosis medicines";"Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)";"Tuberculous meningitis";"J04AD03";;"Added"
"ethosuximide";"Antiseizure medicines";"Oral > Liquid: 250 mg per 5 mL
Oral > Solid: 250 mg";"Absence seizures, typical";"N03AD01";;"Added"
"etonogestrel-releasing implant";"Implantable contraceptives";"Implant > Subdermal: 68 mg single rod";"Contact with health services for insertion of contraceptive device";"G03AC08";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01CB01";;"Removed"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Burkitt lymphoma including Burkitt leukaemia";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Lymphoid leukaemia, not elsewhere classified";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Myeloid leukaemia";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Other specified malignant neoplasms of the ovary";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Other specified malignant neoplasms of bronchus or lung";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Germ cell tumour of testis";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Malignant trophoblastic neoplasms of placenta";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Malignant neoplasms of kidney, except renal pelvis";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Hodgkin lymphoma";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Retinoblastoma";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Anaplastic large cell lymphoma, ALK-negative";"L01CB01";;"Added"
"etoposide";"Cytotoxic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule
Oral > Solid: 100 mg capsule
Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
Oral > Solid: 100 mg capsule; 50 mg capsule";"Anaplastic large cell lymphoma, ALK-positive";"L01CB01";;"Added"
"everolimus";"Targeted therapies";"Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)";"Other specified gliomas of brain";"L01EG02";;"Added"
"fentanyl";"Opioid analgesics";"Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
Oral > Other: 200 to 1200 µg buccal film (as citrate)";"Chronic cancer pain";"N01AH01";;"Added"
"fentanyl";"Opioid analgesics";"Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)
Oral > Other: 200 to 1200 µg buccal film (as citrate)";"Other specified chronic cancer related pain";"N02AB03";;"Removed"
"ferrous salt";"Antianaemia medicines";"Oral > Liquid: 25 mg per  mL iron (as sulfate)
Oral > Solid: 60 mg iron";"Iron deficiency anaemia";"B03AA07, B03AA02";;"Added"
"ferrous salt + folic acid";"Antianaemia medicines";"Oral > Solid: 60 mg iron + 2.8 mg";"Iron deficiency anaemia";"B03AD02, B03AD03, B03AD05";;"Removed"
"fexinidazole";"Medicines for the treatment of 1st stage African trypanosomiasis";"Oral > Solid: 600 mg";"African trypanosomiasis";"P01CA03";;"Added"
"fexinidazole";"Medicines for the treatment of 2nd stage African trypanosomiasis";"Oral > Solid: 600 mg";"African trypanosomiasis";"P01CA03";;"Added"
"fexofenadine";"Antiallergics and medicines used in anaphylaxis";;"Allergic or hypersensitivity conditions of unspecified type";;;"Added"
"fifth generation cephalosporins";"Reserve group antibiotics";".";"Other specified bacterial diseases";;;"Removed"
"filgrastim";"Immunomodulators";"Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per  mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial";"Acquired neutropaenia";"L03AA02";;"Added"
"fingolimod";"Immunomodulators for non-malignant disease";"Oral > Solid: 0.25 mg; 0.5 mg";"Relapsing-remitting multiple sclerosis";"L04AA27";;"Removed"
"fluconazole";"Antifungal medicines";"Parenteral > General injections > IV: 2 mg per  mL in vial
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
Oral > Solid > capsule: 50 mg";"Cryptococcosis";"J02AC01";;"Added"
"fluconazole";"Antifungal medicines";"Parenteral > General injections > IV: 2 mg per  mL in vial
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
Oral > Solid > capsule: 50 mg";"Candidosis";"J02AC01";;"Added"
"flucytosine";"Antifungal medicines";"Parenteral > General injections > IV: 2.5 g per 250 mL infusion
Oral > Solid: 250 mg capsule";"Cryptococcosis";"J02AX01";;"Added"
"fludarabine";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
Oral > Solid: 10 mg tablet (fludarabine phosphate)";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01BB05";;"Added"
"fludrocortisone";"Adrenal hormones and synthetic substitutes";"Oral > Solid: 100 µg (acetate)";"Adrenocortical insufficiency";"H02AA02";;"Added"
"flunisolide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"fluorescein";"Diagnostic agents > Ophthalmic medicines";"Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)";"Fluorescein";"S01JA01";;"Added"
"fluorouracil";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Ointment: 5%";"Plantar warts";"L01BC02";;"Added"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01BC02";;"Removed"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Malignant neoplasms of nasopharynx";"L01BC02";;"Added"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Malignant neoplasm metastasis in large intestine";"L01BC02";;"Added"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Malignant neoplasms of breast";"L01BC02";;"Added"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Malignant neoplasms of rectum";"L01BC02";;"Added"
"fluorouracil";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg per  mL in 5 mL ampoule
Parenteral > General injections > IV: 50 mg per  mL in vial";"Malignant neoplasms of colon";"L01BC02";;"Added"
"flutamide";"Hormones and antihormones";;"Malignant neoplasms of prostate";;;"Added"
"fluticasone";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"fluticasone + formoterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"fluticasone furoate + vilanterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"fluvastatin";"Lipid-lowering agents";;"Mixed hyperlipidaemia";;;"Added"
"fluvastatin";"Lipid-lowering agents";;"Coronary atherosclerosis";;;"Added"
"folic acid";"Antianaemia medicines";"Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg";"Folate deficiency anaemia";"B03BB01";;"Added"
"folic acid";"Antianaemia medicines";"Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg";"Anencephaly or similar anomalies";"B03BB01";;"Added"
"folic acid";"Antianaemia medicines";"Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg";"Spina bifida";"B03BB01";;"Added"
"folic acid";"Antianaemia medicines";"Oral > Solid: 1 mg tablet; 5 mg tablet
Oral > Solid: 400 µg";"Cephalocele";"B03BB01";;"Added"
"fomepizole";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 5 mg per  mL in 20 mL ampoule (sulfate); 1 g per  mL in 1.5 mL ampoule (base)";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB34";;"Added"
"fosfomycin (injection)";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection";"Other specified bacterial diseases";"J01XX01";;"Removed"
"fosfomycin (injection)";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection";"Carbapenem resistant Acinetobacter baumannii";"J01XX01";;"Added"
"fosfomycin (injection)";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection";"Carbapenem-resistant Pseudomonas aeruginosa";"J01XX01";;"Added"
"fosfomycin (injection)";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection";"Carbapenem resistant Enterobacterales";"J01XX01";;"Added"
"fourth generation cephalosporins";"Watch group antibiotics";".";"Other specified bacterial diseases";;;"Removed"
"fresh-frozen plasma";"Blood and blood components";"Parenteral > General injections > IV: ";"Blood transfusion without reported diagnosis";"B05AX03";;"Added"
"fulvestrant";"Hormones and antihormones";"Parenteral > General injections > IV: 250 mg per 5 mL";"Malignant neoplasms of breast";"L02BA03";;"Removed"
"furosemide";"Medicines used in heart failure";"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg";"Heart failure";"C03CA01";;"Added"
"furosemide";"Diuretics";"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg";"Anuria or oliguria";"C03CA01";;"Added"
"furosemide";"Diuretics";"Parenteral > General injections > IV: 10 mg per  mL in 2 mL ampoule; 10 mg per  mL in 5 mL ampoule
Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
Oral > Solid > tablet: 40 mg; 20 mg";"Oedema";"C03CA01";;"Added"
"gabapentin";"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)";"Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg";"Neuropathic pain";"N02BF01";;"Removed"
"gallamine";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 40 mg per  mL in 2 mL ampoule (gallamine triethiodide)";"Muscle relaxants";"M03AC02";;"Removed"
"gatifloxacin";"Antituberculosis medicines";"Oral > Solid: 200 mg; 400 mg";"Multi-drug resistant Mycobacterium tuberculosis";"J01MA16";;"Removed"
"gefitinib";"Targeted therapies";;"Other specified malignant neoplasms of bronchus or lung";;;"Added"
"gemcitabine";"Cytotoxic medicines";"Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection";"Other specified carcinomas of ovary";"L01BC05";;"Added"
"gemcitabine";"Cytotoxic medicines";"Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection";"Other specified malignant neoplasms of bronchus or lung";"L01BC05";;"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Sepsis without septic shock";"J01GB03";"amoxicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Sepsis without septic shock";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Sepsis without septic shock";"J01GB03";"benzylpenicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]";"J01GB03";"benzylpenicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Bacterial pneumonia (Community-acquired pneumonia - severe) [children]";"J01GB03";"amoxicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Acute malnutrition in infants, children or adolescents (complicated) [children]";"J01GB03";"benzylpenicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Acute malnutrition in infants, children or adolescents (complicated) [children]";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Peritonitis (mild-moderate)";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Peritonitis (severe)";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Peritoneal abscess (mild-moderate)";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Peritoneal abscess (severe)";"J01GB03";"ampicillin";"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Neonatal meningitis";"J01GB03";;"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Gonococcal infection";"J01GB03";;"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Other specified prophylactic measures";"J01GB03";;"Added"
"gentamicin";"Access group antibiotics";"Parenteral > General injections > unspecified: 10 mg per  mL in 2 mL vial (as sulfate); 40 mg per  mL in 2 mL vial (as sulfate)";"Bacterial infection of unspecified site";"J01GB03";;"Removed"
"gentamicin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)";"Other specified conjunctivitis";"S02AA14";;"Added"
"gentamicin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)";"Infectious blepharitis";"S02AA14";;"Added"
"glass ionomer cement";"Dental medicines and preparations";"Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid";"Dental caries";;;"Added"
"glatiramer acetate";"Medicines for multiple sclerosis";"Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL
Parenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe";"Relapsing-remitting multiple sclerosis";"L03AX13";;"Removed"
"glatiramer acetate";"Medicines for multiple sclerosis";"Parenteral > General injections > SC: 20 mg per  mL; 40 mg per  mL
Parenteral > General injections > SC: 20 mg per  mL in pre-filled syringe; 40 mg per  mL in pre-filled syringe";"Multiple sclerosis";"L03AX13";;"Added"
"glecaprevir + pibrentasvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules";"Chronic hepatitis C";"J05AP57";;"Added"
"glibenclamide";"Oral hypoglycaemic agents";"Oral > Solid: 5 mg; 2.5 mg";"Type 2 diabetes mellitus";"A10BB01";;"Removed"
"gliclazide";"Oral hypoglycaemic agents";"Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release";"Type 2 diabetes mellitus";"A10BB09";;"Added"
"glucagon";"Medicines for hypoglycaemia";"Parenteral > General injections > unspecified: 1 mg per  mL";"Hypoglycaemia in the context of diabetes";"H04AA01";;"Added"
"glucose";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
Parenteral > General injections > IV: 50% hypertonic";"Other specified disorders of fluid, electrolyte or acid-base balance";"B05CX01";;"Added"
"glucose";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
Parenteral > General injections > IV: 50% hypertonic";"Hypoglycaemia without associated diabetes";"B05CX01";;"Added"
"glucose + sodium chloride";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)";"Other specified disorders of fluid, electrolyte or acid-base balance";;;"Added"
"glutaral";"Disinfectants";"Local > Topical > Solution: 2%";"Glutaral nonmedicinal";;;"Added"
"glyceryl trinitrate";"Antianginal medicines";"Oral > Solid: 500 µg sublingual tablet";"Angina pectoris";"C01DA02";;"Added"
"glycopyrronium";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Chronic obstructive pulmonary disease";;;"Added"
"golimumab";"Immunomodulators for non-malignant disease";;"Axial spondyloarthritis";;;"Added"
"golimumab";"Immunomodulators for non-malignant disease";;"Crohn disease site";;;"Added"
"golimumab";"Immunomodulators for non-malignant disease";;"Rheumatoid arthritis";;;"Added"
"golimumab";"Medicines for juvenile joint diseases";;"Juvenile idiopathic arthritis";;;"Added"
"goserelin";"Hormones and antihormones";;"Malignant neoplasms of breast";;;"Added"
"goserelin";"Hormones and antihormones";;"Malignant neoplasms of prostate";;;"Added"
"granisetron";"Medicines for other common symptoms in palliative care";;"Palliative care";;;"Added"
"granisetron";"Antiemetic medicines";;"Nausea or vomiting";;;"Added"
"griseofulvin";"Antifungal medicines";"Oral > Liquid: 125 mg per 5 mL
Oral > Solid: 125 mg; 250 mg";"Dermatophytosis";"D01BA01";;"Added"
"haemophilus influenzae type b vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against single bacterial diseases";"J07AG01";;"Added"
"haloperidol";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 2 mg per  mL
Oral > Solid: 0.5 mg; 2 mg; 5 mg
Parenteral > General injections > unspecified: 5 mg per  mL in 1-mL ampoule";"Palliative care";"N05AD01";;"Added"
"halothane";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation > liquid: ";"Anaesthetics and therapeutic gases";"N01AB01";;"Added"
"heparin sodium";"Medicines affecting coagulation";"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule";"Acute ischaemic heart disease";"B01AB01";;"Added"
"heparin sodium";"Medicines affecting coagulation";"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule";"Unstable angina";"B01AB01";;"Added"
"heparin sodium";"Medicines affecting coagulation";"Parenteral > General injections > IV: 1000 IU per  mL in 5 mL ampoule; 20000 IU per  mL in 5 mL ampoule; 5000 IU per  mL in 5 mL ampoule";"Venous thromboembolism";"B01AB01";;"Added"
"hepatitis a vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against viral hepatitis";"J07BC02";;"Added"
"hepatitis b vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against viral hepatitis";"J07BC01";;"Added"
"homatropine";"Ophthalmological preparations > Mydriatics";"Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
";"Anterior uveitis";"S01FA05";;"Removed"
"homatropine";"Ophthalmological preparations > Mydriatics";"Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
";"Anterior uveitis";;;"Added"
"human papilloma virus (HPV) vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BM01";;"Added"
"hydralazine";"Antihypertensive medicines";"Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)";"Essential hypertension";"C02DB02";;"Removed"
"hydralazine";"Antihypertensive medicines";"Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)";"Gestational hypertension";"C02DB02";;"Added"
"hydrochlorothiazide";"Antihypertensive medicines";"Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 25 mg; 12.5 mg";"Essential hypertension";"C03AA03";;"Added"
"hydrochlorothiazide";"Medicines used in heart failure";"Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 25 mg";"Heart failure";"C03AA03";;"Added"
"hydrochlorothiazide";"Diuretics";"Oral > Solid: 25 mg";"Oedema";"C03AA03";;"Added"
"hydrocortisone";"Hormones and antihormones";"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)";"Lymphoid leukaemia, not elsewhere classified";"H02AB09";;"Added"
"hydrocortisone";"Hormones and antihormones";"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"H02AB09";;"Removed"
"hydrocortisone";"Hormones and antihormones";"Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)";"Burkitt lymphoma including Burkitt leukaemia";"H02AB09";;"Added"
"hydrocortisone";"Adrenal hormones and synthetic substitutes";"Oral > Solid: 5 mg; 10 mg; 20 mg";"Adrenocortical insufficiency";"H02AB09";;"Added"
"hydrocortisone";"Ophthalmological preparations > Anti-inflammatory agents";"Local > Ophthalmological > Ointment: 1% (acetate)";"Scleritis";"S01BA02";;"Removed"
"hydrocortisone";"Ophthalmological preparations > Anti-inflammatory agents";"Local > Ophthalmological > Ointment: 1% (acetate)";"Anterior uveitis";"S01BA02";;"Removed"
"hydrocortisone";"Antiallergics and medicines used in anaphylaxis";"Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)";"Anaphylaxis";"H02AB09";;"Added"
"hydrocortisone";"Anti-inflammatory medicines";"Local > Rectal > Suppository: 25 mg (acetate)
Local > Rectal > Retention enema: 100 mg per 60 mL";"Crohn disease site";"A07EA02";;"Added"
"hydrocortisone";"Anti-inflammatory medicines";"Local > Rectal > Suppository: 25 mg (acetate)
Local > Rectal > Retention enema: 100 mg per 60 mL";"Ulcerative colitis";"A07EA02";;"Added"
"hydrocortisone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)";"Dermatitis or eczema";"D07AA02";;"Added"
"hydrocortisone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)";"Lichen planus";"D07AA02";;"Added"
"hydrocortisone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)";"Pruritus due to skin disorder";"D07AA02";;"Added"
"hydrocortisone";"Dermatological medicines > Anti-inflammatory and antipruritic medicines";"Local > Topical > Cream: 1% (acetate)
Local > Topical > Ointment: 1% (acetate)";"Psoriasis of unspecified type";"D07AA02";;"Added"
"hydromorphone";"Opioid analgesics";;"Pain";;;"Added"
"hydroxocobalamin";"Antianaemia medicines";"Parenteral > General injections > IM: 1 mg per  mL in 1 mL ampoule (as acetate); 1 mg per  mL in 1 mL ampoule (as hydrochloride); 1 mg per  mL in 1 mL ampoule (as sulfate)";"Megaloblastic anaemia due to vitamin B12 deficiency";"B03BA03";;"Added"
"hydroxycarbamide (hydroxyurea)";"Cytotoxic medicines";"Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg";"Squamous cell carcinoma of oropharynx";"L01XX05";;"Removed"
"hydroxycarbamide (hydroxyurea)";"Cytotoxic medicines";"Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg";"Chronic myeloid leukaemia, not elsewhere classified";"L01XX05";;"Added"
"hydroxycarbamide (hydroxyurea)";"Other medicines for haemoglobinopathies";"Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg";"Other specified sickle cell disorders or other haemoglobinopathies";"L01XX05";;"Added"
"hydroxychloroquine";"Antimalarial medicines > For chemoprevention";;"Malaria due to Plasmodium falciparum";;;"Removed"
"hydroxychloroquine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 200 mg (as sulfate)";"Systemic lupus erythematosus";"P01BA02";;"Added"
"hydroxychloroquine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 200 mg (as sulfate)";"Cutaneous lupus erythematosus of unspecified type";"P01BA02";;"Added"
"hyoscine butylbromide";"Medicines for other common symptoms in palliative care";"Parenteral > General injections > unspecified: 20 mg per  mL injection";"Palliative care";"A03BB01";;"Added"
"hyoscine hydrobromide";"Medicines for other common symptoms in palliative care";"Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
Parenteral > General injections > unspecified: 400 µg per  mL injection; 600 µg per  mL injection";"Palliative care";"A04AD01";;"Added"
"hypochlorous acid";"Antiseptics";"Local > Topical > Solution: ";"Disinfectant, not elsewhere classified";;;"Removed"
"ibrutinib";"Targeted therapies";"Oral > Solid: 140 mg";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01EL01";;"Added"
"ibuprofen";"Medicines administered to the neonate [c]";"Parenteral > General injections > IV: 5 mg per  mL";"Patent arterial duct";"C01EB16";;"Added"
"ibuprofen";"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)";"Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
Oral > Solid > tablet: 200 mg; 400 mg; 600 mg";"Pain";"M01AE01";;"Added"
"ibuprofen";"Antimigraine medicines > For treatment of acute attack";"Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
Oral > Solid > tablet: 200 mg; 400 mg";"Migraine";"M01AE01";;"Added"
"idoxuridine";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 0.1%
Local > Ophthalmological > Ointment: 0.2%";"Herpes simplex keratitis";"S01AD01";;"Removed"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Other specified malignant neoplasms of the ovary";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Germ cell tumour of testis";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Rhabdomyosarcoma primary site";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01AA06";;"Removed"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Burkitt lymphoma including Burkitt leukaemia";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Malignant neoplasms of kidney, except renal pelvis";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Anaplastic large cell lymphoma, ALK-negative";"L01AA06";;"Added"
"ifosfamide";"Cytotoxic medicines";"Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection";"Anaplastic large cell lymphoma, ALK-positive";"L01AA06";;"Added"
"imatinib";"Targeted therapies";"Oral > Solid: 100 mg; 400 mg";"B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1";"L01EA01";;"Added"
"imatinib";"Targeted therapies";"Oral > Solid: 100 mg; 400 mg";"Gastrointestinal stromal tumour of unspecified gastrointestinal sites";"L01EA01";;"Added"
"imatinib";"Targeted therapies";"Oral > Solid: 100 mg; 400 mg";"Chronic myeloid leukaemia, not elsewhere classified";"L01EA01";;"Added"
"imipenem + cilastatin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
";"Peritonitis (severe)";"J01DH02";;"Added"
"imipenem + cilastatin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
";"Peritoneal abscess (severe)";"J01DH02";;"Added"
"imipenem + cilastatin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
";"Neutropenia (high-risk)";"J01DH02";;"Added"
"imipenem + cilastatin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
";"Pseudomonas aeruginosa resistant to other antibiotic";"J01DH51";;"Removed"
"imipenem + cilastatin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
";"Antibiotic resistant Acinetobacter baumannii";"J01DH51";;"Removed"
"imipenem + cilastatin";"Antituberculosis medicines";;"Multi-drug resistant Mycobacterium tuberculosis";;;"Added"
"imipenem + cilastatin + relebactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection";"Other specified other antibiotic resistant Enterobacterales";"J01DH56";;"Removed"
"imipenem + cilastatin + relebactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection";"Carbapenem resistant Enterobacterales";"J01DH56";;"Removed"
"imipenem + cilastatin + relebactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection";"Carbapenem-resistant Pseudomonas aeruginosa";"J01DH56";;"Removed"
"indapamide";"Antihypertensive medicines";;"Essential hypertension";;;"Added"
"indapamide";"Medicines used in heart failure";;"Heart failure";;;"Added"
"indinavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 400 mg (as sulfate)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE02";;"Removed"
"indometacin";"Medicines administered to the neonate [c]";;"Patent arterial duct";;;"Added"
"infliximab";"Immunomodulators for non-malignant disease";;"Axial spondyloarthritis";;;"Added"
"infliximab";"Immunomodulators for non-malignant disease";;"Crohn disease site";;;"Added"
"infliximab";"Immunomodulators for non-malignant disease";;"Rheumatoid arthritis";;;"Added"
"infliximab";"Medicines for juvenile joint diseases";;"Juvenile idiopathic arthritis";;;"Added"
"influenza vaccine (seasonal)";"Recommendations for immunization programmes with certain characteristics";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against influenza";"J07BB01, J07BB02, J07BB03";;"Added"
"insulin analogues";"Insulins";"Not specified";"Type 1 diabetes mellitus";"A10AE04, A10AE05, A10AB05, A10AD05, A10AB04, A10AC04, A10AD04, A10AB06, A10AE06";;"Removed"
"insulin analogues";"Insulins";"Not specified";"Type 2 diabetes mellitus";"A10AE04, A10AE05, A10AB05, A10AD05, A10AB04, A10AC04, A10AD04, A10AB06, A10AE06";;"Removed"
"insulin degludec";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 1 diabetes mellitus";;;"Removed"
"insulin degludec";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 1 diabetes mellitus";;;"Added"
"insulin degludec";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 2 diabetes mellitus";;;"Added"
"insulin detemir";"Insulins";;"Type 1 diabetes mellitus";;;"Removed"
"insulin detemir";"Insulins";;"Type 1 diabetes mellitus";;;"Added"
"insulin detemir";"Insulins";;"Type 2 diabetes mellitus";;;"Added"
"insulin glargine";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 1 diabetes mellitus";"A10AE04";;"Removed"
"insulin glargine";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 1 diabetes mellitus";;;"Added"
"insulin glargine";"Insulins";"Parenteral > General injections > SC: 100 units per  mL
";"Type 2 diabetes mellitus";;;"Added"
"intraperitoneal dialysis solution";"Peritoneal dialysis solution";"parenteral solution";"Care involving peritoneal dialysis";;;"Added"
"iodine";"Vitamins and minerals";"Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
Oral > Solid: 190 mg";"Iodine deficiency";"H03CA";;"Added"
"iodine";"Antiseptics";;"Povidone iodine";;;"Added"
"iohexol";"Diagnostic agents > Radiocontrast media";"Parenteral > General injections > unspecified: 140 to 350 mg iodine per  mL in 5 mL ampoule; 140 to 350 mg iodine per  mL in 10 mL ampoule; 140 to 350 mg iodine per  mL in 20 mL ampoule";"X-ray contrast media, iodinated";"V08AB02";;"Added"
"ipecacuanha";"Antidotes and other substances used in poisonings > Non-specific";"Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine";"Unspecified injury, poisoning or certain other consequences of external causes";"V03AB01";;"Removed"
"ipratropium bromide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Respiratory > Inhalation > aerosol: 20 µg per  dose";"Asthma";"R03BB01";;"Added"
"ipratropium bromide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Respiratory > Inhalation > aerosol: 20 µg per  dose";"Chronic obstructive pulmonary disease";"R03BB01";;"Added"
"irinotecan";"Cytotoxic medicines";"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial";"Malignant neoplasm metastasis in large intestine";"L01CE02";;"Added"
"irinotecan";"Cytotoxic medicines";"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial";"Malignant neoplasms of kidney, except renal pelvis";"L01CE02";;"Added"
"irinotecan";"Cytotoxic medicines";"Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial";"Rhabdomyosarcoma primary site";"L01CE02";;"Added"
"isoflurane";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation > liquid: ";"Anaesthetics and therapeutic gases";"N01AB06";;"Added"
"isoniazid";"Antituberculosis medicines";"Parenteral > General injections > IV: 100 mg per  mL
Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet";"Other specified tuberculosis";"J04AC01";;"Removed"
"isoniazid";"Antituberculosis medicines";"Parenteral > General injections > IV: 100 mg per  mL
Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet";"Tuberculosis";"J04AC01";;"Added"
"isoniazid + pyrazinamide + rifampicin";"Antituberculosis medicines";"Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)";"Tuberculosis";"J04AM05";;"Added"
"isoniazid + pyridoxine + sulfamethoxazole + trimethoprim";"Medicines for prevention of HIV-related opportunistic infections";"Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)";"Other specified prophylactic measures";"J04AC51";;"Added"
"isoniazid + rifampicin";"Antituberculosis medicines";"Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet";"Tuberculosis";"J04AM02";;"Added"
"isoniazid + rifapentine";"Antituberculosis medicines";"Oral > Solid: 300 mg + 300 mg tablet (scored)";"Latent tuberculosis";"J04AC51";;"Added"
"isoprenaline";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 20 µg per  mL in ampoule (hydrochloride)
Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)";"Bradycardia";"C01CA02";;"Removed"
"isoprenaline";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 20 µg per  mL in ampoule (hydrochloride)
Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)";"Cardiogenic shock";"C01CA02";;"Removed"
"isosorbide dinitrate";"Antianginal medicines";"Oral > Solid: 5 mg sublingual tablet";"Angina pectoris";"C01DA08";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Chronic pulmonary aspergillosis";"J02AC02";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Chromoblastomycosis";"J02AC02";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Histoplasmosis";"J02AC02";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Talaromycosis";"J02AC02";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Sporotrichosis";"J02AC02";;"Added"
"itraconazole";"Antifungal medicines";"Oral > Liquid: 10 mg per  mL
Oral > Solid: 100 mg";"Paracoccidioidomycosis";"J02AC02";;"Added"
"ivermectin";"Intestinal anthelminthics";"Oral > Solid > tablet: 3 mg";"Strongyloidiasis";"P02CF01";;"Added"
"ivermectin";"Intestinal anthelminthics";"Oral > Solid > tablet: 3 mg";"Ascariasis";"P02CF01";;"Added"
"ivermectin";"Intestinal anthelminthics";"Oral > Solid > tablet: 3 mg";"Trichuriasis";"P02CF01";;"Added"
"ivermectin";"Intestinal anthelminthics";"Oral > Solid > tablet: 3 mg";"Hookworm diseases";"P02CF01";;"Added"
"ivermectin";"Intestinal anthelminthics";"Oral > Solid > tablet: 3 mg";"Ancylostomiasis";"P02CF01";;"Added"
"ivermectin";"Antifilarials";"Oral > Solid > tablet: 3 mg";"Onchocerciasis";"P02CF01";;"Added"
"ivermectin";"Antifilarials";"Oral > Solid > tablet: 3 mg";"Lymphatic filariasis";"P02CF01";;"Added"
"ivermectin";"Medicines for ectoparasitic infections";"Oral > Solid > tablet: 3 mg";"Scabies";"P02CF01";;"Added"
"kanamycin";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"kanamycin";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"kanamycin (injection)";"Antituberculosis medicines";"Parenteral > General injections > IV: 1000 mg powder for injection (vial)";"Multi-drug resistant Mycobacterium tuberculosis";"J01GB04";;"Removed"
"ketamine";"General anaesthetics and oxygen > Injectable medicines";"Parenteral > General injections > unspecified: 50 mg per  mL in 10 mL vial (as hydrochloride)";"Anaesthetics and therapeutic gases";"N01AX03";;"Added"
"lactulose";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid";"Palliative care";"A06AD11";;"Added"
"lamivudine";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 150 mg tablet";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF05";;"Added"
"lamivudine + nevirapine + zidovudine";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR05";;"Removed"
"lamivudine + tenofovir";"Fixed-dose combinations of antiretrovirals";;"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";;;"Added"
"lamivudine + tenofovir";"Fixed-dose combinations of antiretrovirals";;"Contact with or exposure to human immunodeficiency virus";;;"Added"
"lamivudine + zidovudine";"Fixed-dose combinations of antiretrovirals";"Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR01";;"Added"
"lamotrigine";"Antiseizure medicines";"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)";"Epilepsy or seizures";"N03AX09";;"Added"
"latanoprost";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 50 µg per  mL eye drops";"Primary open-angle glaucoma";"S01EE01";;"Added"
"ledipasvir + sofosbuvir";"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations";"Oral > Solid: 90 mg + 400 mg tablet";"Chronic hepatitis C";"J05AP51";;"Added"
"lenalidomide";"Immunomodulators";"Oral > Solid: 25 mg";"Plasma cell myeloma";"L04AX04";;"Added"
"leuprorelin";"Hormones and antihormones";"Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe";"Malignant neoplasms of breast";"L02AE02";;"Added"
"leuprorelin";"Hormones and antihormones";"Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe";"Malignant neoplasms of prostate";"L02AE02";;"Added"
"levamisole";"Intestinal anthelminthics";"Oral > Solid > tablet: 50 mg  (as hydrochloride); 150 mg  (as hydrochloride)";"Ascariasis";"P02CE01";;"Added"
"levetiracetam";"Antiseizure medicines";"Oral > Liquid: 100 mg per  mL
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag";"Epilepsy or seizures";"N03AX14";;"Added"
"levetiracetam";"Antiseizure medicines";"Oral > Liquid: 100 mg per  mL
Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per  mL in 100 mL bag; 10 mg per  mL in 100 mL bag; 15 mg per  mL in 100 mL bag";"Status epilepticus";"N03AX14";;"Added"
"levodopa";"Antiseizure medicines";"Oral > Solid: 250 mg";"Parkinson disease";"N04BA01";;"Removed"
"levodopa + benserazide";"Medicines for parkinsonism";;"Parkinson disease";;;"Added"
"levodopa + carbidopa";"Medicines for parkinsonism";"Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet";"Parkinson disease";"N04BA02";;"Added"
"levofloxacin";"Antituberculosis medicines";"Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)";"Multi-drug resistant Mycobacterium tuberculosis";"J01MA12";;"Added"
"levonorgestrel";"Oral hormonal contraceptives";"Oral > Solid: 750 µg [2]; 1.5 mg [1]
Oral > Solid: 30 µg";"Contact with health services for postcoital contraception";"G03AD01";;"Added"
"levonorgestrel";"Oral hormonal contraceptives";"Oral > Solid: 750 µg [2]; 1.5 mg [1]
Oral > Solid: 30 µg";"Contact with health services for contraceptive management";"G03AC03";;"Added"
"levonorgestrel";"Intrauterine devices";"Intrauterine system with reservoir containing 52 mg of levonorgestrel.";"Contact with health services for insertion of contraceptive device";"G02BA03";;"Added"
"levonorgestrel-releasing implant";"Implantable contraceptives";"Implant > Subdermal: 75 mg per  rod (two-rods)";"Contact with health services for insertion of contraceptive device";"G03AC03";;"Added"
"levothyroxine";"Thyroid hormones and antithyroid medicines";"Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)";"Hypothyroidism";"H03AA01";;"Added"
"lidocaine";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 20 mg per  mL in 5 mL ampoule (hydrochloride)";"Ventricular tachyarrhythmia";"C01BB01";;"Added"
"lidocaine";"Local anaesthetics";"Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
Local > Topical > unspecified: 2 to 4% (hydrochloride)";"Local anaesthetics";"N01BB02";;"Added"
"lidocaine + epinephrine";"Local anaesthetics";"Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine";"Local anaesthetics";"N01BB52";;"Added"
"lindane";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Cream: 1%
Local > Topical > Lotion: 1%";"Scabies";"P03AB02";;"Removed"
"linezolid";"Reserve group antibiotics";"Parenteral > General injections > IV: 2 mg per  mL in 300 mL bag
Oral > Liquid: 100 mg per 5 mL powder for oral liquid
Oral > Solid: 400 mg tablet; 600 mg tablet";"Other specified bacterial diseases";"J01XX08";;"Removed"
"linezolid";"Antituberculosis medicines";"Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)";"Multi-drug resistant Mycobacterium tuberculosis";"J01XX08";;"Added"
"lisinopril + amlodipine";"Antihypertensive medicines";"Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg";"Essential hypertension";"C09BB03";;"Added"
"lisinopril + hydrochlorothiazide";"Antihypertensive medicines";"Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg";"Essential hypertension";"C09BA03";;"Added"
"lisocabtagene maraleucel";"Antineoplastics and supportive medicines";;"Diffuse large B-cell lymphomas";;;"Removed"
"lithium carbonate";"Medicines for bipolar disorders";"Oral > Solid: 300 mg";"Bipolar or related disorders";"N05AN01";;"Added"
"long-acting insulin analogues";"Insulins";"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen";"Type 1 diabetes mellitus";"A10AE06, A10AE05, A10AE04";;"Added"
"long-acting insulin analogues";"Insulins";"Parenteral > General injections > SC: 100 IU per  mL in 3 mL cartridge; 100 IU per  mL in 3 mL pre-filled pen";"Type 2 diabetes mellitus";"A10AE06, A10AE05, A10AE04";;"Added"
"loperamide";"Medicines for other common symptoms in palliative care";"Oral > Solid: 2 mg solid oral dosage form";"Palliative care";"A07DA03";;"Added"
"lopinavir + ritonavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AR10";;"Added"
"loratadine";"Antiallergics and medicines used in anaphylaxis";"Oral > Liquid: 1 mg per  mL
Oral > Solid: 10 mg";"Allergic or hypersensitivity conditions of unspecified type";"R06AX13";;"Added"
"lorazepam";"Antiseizure medicines";"Parenteral > General injections > IV: 2 mg per  mL in 1 mL ampoule; 4 mg per  mL in 1 mL ampoule";"Status epilepticus";"N05BA06";;"Added"
"losartan";"Antihypertensive medicines";"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet";"Essential hypertension";"C09CA01";;"Added"
"losartan";"Medicines used in heart failure";"Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet";"Heart failure";"C09CA01";;"Added"
"lovastatin";"Lipid-lowering agents";;"Mixed hyperlipidaemia";;;"Added"
"lovastatin";"Lipid-lowering agents";;"Coronary atherosclerosis";;;"Added"
"lugol's solution";"Thyroid hormones and antithyroid medicines";"Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)";"Thyrotoxicosis";"H03CA";;"Added"
"magnesium sulfate";"Antiseizure medicines";"Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
Parenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)";"Severe pre-eclampsia";"B05XA05";;"Added"
"magnesium sulfate";"Antiseizure medicines";"Parenteral > General injections > IV: 500 mg per  mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
Parenteral > General injections > IM: 500 mg per  mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)";"Eclampsia";"B05XA05";;"Added"
"mannitol";"Diuretics";"Parenteral > General injections > IV: 10% solution; 20% solution";"Ocular hypertension";"B05BC01";;"Added"
"mannitol";"Diuretics";"Parenteral > General injections > IV: 10% solution; 20% solution";"Cerebral oedema";"B05BC01";;"Added"
"measles vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against measles alone";"J07BD01";;"Added"
"mebendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)";"Ascariasis";"P02CA01";;"Added"
"mebendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)";"Enterobiasis";"P02CA01";;"Added"
"mebendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)";"Trichuriasis";"P02CA01";;"Added"
"mebendazole";"Intestinal anthelminthics";"Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)";"Hookworm diseases";"P02CA01";;"Added"
"mebendazole";"Cysticidal medicines";"Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)";"Other specified echinococcosis";"P02CA01";;"Added"
"medroxyprogesterone acetate";"Injectable hormonal contraceptives";"Parenteral > General injections > IM: 150 mg per  mL in 1 mL vial
Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system";"Contact with health services for reasons associated with reproduction";"G03AC06";;"Added"
"medroxyprogesterone acetate";"Progestogens";"Oral > Solid: 5 mg";"Excessive menstruation with irregular cycle";"G03DA02";;"Added"
"mefloquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 250 mg tablet (hydrochloride)";"Malaria due to Plasmodium falciparum";"P01BC02";;"Added"
"mefloquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 250 mg tablet (hydrochloride)";"Malaria due to Plasmodium vivax";"P01BC02";;"Added"
"mefloquine";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 250 mg tablet (hydrochloride)";"Malaria due to Plasmodium falciparum";"P01BC02";;"Added"
"meglumine antimoniate";"Antileishmaniasis medicines";"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule";"Visceral leishmaniasis";"P01CB01";;"Added"
"meglumine antimoniate";"Antileishmaniasis medicines";"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule";"Mucocutaneous leishmaniasis";"P01CB01";;"Added"
"meglumine antimoniate";"Antileishmaniasis medicines";"Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule";"Cutaneous leishmaniasis";"P01CB01";;"Added"
"meglumine iotroxate";"Diagnostic agents > Radiocontrast media";"Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL";"X-ray contrast media, iodinated";"V08AC02";;"Added"
"melarsoprol";"Medicines for the treatment of 2nd stage African trypanosomiasis";"Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)";"African trypanosomiasis";"P01CD01";;"Added"
"melphalan";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection
Oral > Solid: 2 mg";"Plasma cell myeloma";"L01AA03";;"Added"
"meningococcal meningitis vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against single bacterial diseases";"J07AH01, J07AH02, J07AH03, J07AH04, J07AH05, J07AH06, J07AH07, J07AH08, J07AH09, J07AH10";;"Added"
"mercaptopurine";"Cytotoxic medicines";"Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01BB02";;"Removed"
"mercaptopurine";"Cytotoxic medicines";"Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01BB02";;"Added"
"mercaptopurine";"Cytotoxic medicines";"Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL";"Lymphoid leukaemia, not elsewhere classified";"L01BB02";;"Added"
"mercaptopurine";"Cytotoxic medicines";"Oral > Solid: 50 mg tablet
Oral > Liquid: 20 mg per  mL";"Langerhans cell histiocytosis";"L01BB02";;"Added"
"meropenem";"Watch group antibiotics";"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection";"Neonatal meningitis";"J01DH02";;"Added"
"meropenem";"Watch group antibiotics";"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection";"Peritonitis (severe)";"J01DH02";;"Added"
"meropenem";"Watch group antibiotics";"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection";"Peritoneal abscess (severe)";"J01DH02";;"Added"
"meropenem";"Watch group antibiotics";"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection";"Neutropenia (high-risk)";"J01DH02";;"Added"
"meropenem";"Antituberculosis medicines";"Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection";"Multi-drug resistant Mycobacterium tuberculosis";"J01DH02";;"Added"
"meropenem + vaborbactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection";"Carbapenem-resistant Pseudomonas aeruginosa";"J01DH52";;"Added"
"meropenem + vaborbactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection";"Carbapenem resistant Enterobacterales";"J01DH52";;"Added"
"meropenem + vaborbactam";"Reserve group antibiotics";"Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection";"Carbapenem resistant Acinetobacter baumannii";"J01DH52";;"Added"
"mesalazine";"Anti-inflammatory medicines";;"Crohn disease site";;;"Added"
"mesalazine";"Anti-inflammatory medicines";;"Ulcerative colitis";;;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Osteosarcoma of bone and articular cartilage of other specified sites";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Other specified malignant neoplasms of the ovary";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Germ cell tumour of testis";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Rhabdomyosarcoma primary site";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"V03AF01";;"Removed"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Burkitt lymphoma including Burkitt leukaemia";"V03AF01";;"Added"
"mesna";"Supportive medicines";"Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule
Oral > Solid: 400 mg; 600 mg";"Malignant neoplasms of kidney, except renal pelvis";"V03AF01";;"Added"
"metformin";"Oral hypoglycaemic agents";"Oral > Solid: 500 mg (hydrochloride)";"Type 2 diabetes mellitus";"A10BA02";;"Added"
"methadone";"Medicines for opioid use disorders";"Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)";"Opioid dependence";"N07BC02";;"Added"
"methadone";"Opioid analgesics";"Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per  mL concentrate for oral liquid (methadone hydrochloride); 10 mg per  mL concentrate for oral liquid (methadone hydrochloride)
Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)";"Chronic cancer pain";"N07BC02";;"Added"
"methimazole";"Thyroid hormones and antithyroid medicines";"Oral > Solid: 5 mg; 10 mg; 20 mg";"Thyrotoxicosis";"H03BB02";;"Added"
"methionine";"Antidotes and other substances used in poisonings > Specific";"Oral > Solid: 250 mg (DL)";"Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs";"V03AB26";;"Removed"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01BA01";;"Removed"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Lymphoid leukaemia, not elsewhere classified";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Acute myeloid leukaemia with recurrent genetic abnormalities";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Malignant trophoblastic neoplasms of placenta";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Burkitt lymphoma including Burkitt leukaemia";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Malignant neoplasms of breast";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Osteosarcoma of bone and articular cartilage of unspecified sites";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Anaplastic large cell lymphoma, ALK-negative";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Anaplastic large cell lymphoma, ALK-positive";"L01BA01";;"Added"
"methotrexate";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)
Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection";"Langerhans cell histiocytosis";"L01BA01";;"Added"
"methotrexate";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)";"Psoriasis of unspecified type";"L04AX03";;"Added"
"methotrexate";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid > tablet: 2.5 mg (as sodium salt)";"Rheumatoid arthritis, serology unspecified";"L04AX03";;"Added"
"methotrexate";"Immunomodulators for non-malignant disease";"Parenteral > General injections > SC: pre-filled syringe in multiple strengths";"Crohn disease site";"L04AX03";;"Removed"
"methotrexate";"Immunomodulators for non-malignant disease";"Parenteral > General injections > SC: pre-filled syringe in multiple strengths";"Psoriatic arthritis";"L04AX03";;"Removed"
"methotrexate";"Medicines for juvenile joint diseases";"Oral > Solid > tablet: 2.5 mg (as sodium salt)";"Juvenile idiopathic arthritis";"L04AX03";;"Added"
"methoxy polyethylene glycol-epoetin beta";"Antianaemia medicines";;"Anaemia due to chronic disease";;;"Added"
"methyldopa";"Antihypertensive medicines";"Oral > Solid: 250 mg";"Essential hypertension";"C02AB01";;"Removed"
"methyldopa";"Antihypertensive medicines";"Oral > Solid: 250 mg";"Gestational hypertension";"C02AB01";;"Added"
"methylergometrine";"Uterotonics";;"Postpartum haemorrhage";;;"Added"
"methylphenidate";"Medicines for mental and behavioural disorders";"Multiple formulations and strengths.";"Attention deficit hyperactivity disorder";"N06BA04";;"Removed"
"methylprednisolone";"Hormones and antihormones";"Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)";"Lymphoid leukaemia, not elsewhere classified";"H02AB04";;"Added"
"methylprednisolone";"Hormones and antihormones";"Parenteral > General injections > IV: 40 mg per  mL in 1 mL single-dose vial (as sodium succinate); 40 mg per  mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per  mL in 1 mL single-dose vial (as sodium succinate)";"Burkitt lymphoma including Burkitt leukaemia";"H02AB04";;"Added"
"methylthioninium chloride";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 10 mg per  mL in 10 mL ampoule";"Acquired methaemoglobinaemia";"V03AB17";;"Added"
"metoclopramide";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 5 mg per 5 mL
Oral > Solid: 10 mg (hydrochloride)
Parenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)";"Palliative care";"A03FA01";;"Added"
"metoclopramide";"Antiemetic medicines";"Oral > Liquid: 5 mg per 5 mL
Oral > Solid: 10 mg (hydrochloride)
Parenteral > General injections > unspecified: 5 mg per  mL in 2 mL ampoule (hydrochloride)";"Nausea or vomiting";"A03FA01";;"Added"
"metoprolol";"Antianginal medicines";;"Angina pectoris";;;"Added"
"metoprolol";"Medicines used in heart failure";;"Heart failure";;;"Added"
"metoprolol";"Antihypertensive medicines";;"Essential hypertension";;;"Added"
"metoprolol";"Antiarrhythmic medicines";;"Cardiac arrhythmia";;;"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritonitis (mild-moderate)";"A01AB17";"cefotaxime";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritonitis (severe)";"A01AB17";"cefotaxime";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritonitis (mild-moderate)";"A01AB17";"ceftriaxone";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritonitis (severe)";"A01AB17";"ceftriaxone";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritoneal abscess (mild-moderate)";"A01AB17";"cefotaxime";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritoneal abscess (severe)";"A01AB17";"cefotaxime";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritoneal abscess (mild-moderate)";"A01AB17";"ceftriaxone";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritoneal abscess (severe)";"A01AB17";"ceftriaxone";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Other specified prophylactic measures";"A01AB17";"cefazolin";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritonitis (mild-moderate)";"A01AB17";"ciprofloxacin";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Peritoneal abscess (mild-moderate)";"A01AB17";"ciprofloxacin";"Added"
"metronidazole";"Access group antibiotics";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Oral > Solid: 200 to 500 mg tablet
Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
Local > Rectal > Suppository: 500 mg suppository; 1 g suppository";"Bacterial infection of unspecified site";"A01AB17";;"Removed"
"metronidazole";"Antiamoebic and antigiardiasis medicines";"Oral > Liquid: 200 mg per 5 mL (as benzoate)
Parenteral > General injections > unspecified: 500 mg in 100 mL vial
Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg";"Amoebiasis";"P01AB01";;"Added"
"micafungin";"Antifungal medicines";"Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection";"Systemic or invasive candidosis";"J02AX05";;"Added"
"miconazole";"Dermatological medicines > Antifungal medicines";"Local > Topical > Cream: 2% (nitrate)
Local > Topical > Ointment: 2% (nitrate)";"Fungal infection of the skin";"D01AC02";;"Added"
"midazolam";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 2 mg per  mL oral liquid
Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
Parenteral > General injections > unspecified: 1 mg per  mL injection; 5 mg per  mL injection";"Palliative care";"N05CD08";;"Added"
"midazolam";"Antiseizure medicines";"
Parenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)
Local > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)";"Status epilepticus";;;"Added"
"midazolam";"Antiseizure medicines";"
Parenteral > General injections > unspecified: 1 mg per  mL in 5 mL vial (for buccal administration); 5 mg per  mL in 1 mL vial (for buccal administration); 5 mg per  mL in 3 mL vial (for buccal administration)
Local > Buccal > Solution: 5 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per  mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per  mL in 0.75 mL pre-filled syringe; 10 mg per  mL in 1 mL pre-filled syringe (for oromucosal administration)";"Status epilepticus";"N05CD08";;"Added"
"midazolam";"Preoperative medication and sedation for short-term procedures";"Parenteral > General injections > IV: 1 mg per  mL
Oral > Liquid: 2 mg per  mL
Oral > Solid: 15 mg  tablet; 7.5 mg tablet";"Sedative-hypnotic and anxiolytic drugs";"N05CD08";;"Added"
"mifepristone - misoprostol";"Uterotonics";"Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package";"Induced abortion";"G03XB51";;"Added"
"miltefosine";"Antileishmaniasis medicines";"Oral > Solid: 10 mg; 50 mg";"Visceral leishmaniasis";"P01CX04";;"Added"
"miltefosine";"Antileishmaniasis medicines";"Oral > Solid: 10 mg; 50 mg";"Mucocutaneous leishmaniasis";"P01CX04";;"Added"
"miltefosine";"Antileishmaniasis medicines";"Oral > Solid: 10 mg; 50 mg";"Cutaneous leishmaniasis";"P01CX04";;"Added"
"misoprostol";"Uterotonics";"Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg";"Spontaneous abortion, incomplete, without complication";"G02AD06";;"Added"
"misoprostol";"Uterotonics";"Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg";"Unspecified obstetric condition";"G02AD06";;"Added"
"misoprostol";"Uterotonics";"Oral > Solid: 200 µg
Local > Vaginal > tablet: 25 µg";"Postpartum haemorrhage";"G02AD06";;"Added"
"mometasone";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"mometasone + formoterol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"morphine";"Preoperative medication and sedation for short-term procedures";"Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)";"Opioids or related analgesics and agents affecting opioid receptors";"N02AA01";;"Added"
"morphine";"Opioid analgesics";"Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)";"Pain";"N02AA01";;"Added"
"moxifloxacin";"Antituberculosis medicines";"Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
Oral > Solid: 400 mg tablet";"Multi-drug resistant Mycobacterium tuberculosis";"J01MA14";;"Added"
"moxifloxacin";"Antituberculosis medicines";"Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
Oral > Solid: 400 mg tablet";"Tuberculosis";"J01MA14";;"Added"
"multiple micronutrient powder";"Vitamins and minerals";"Oral > Other: ";"Iron deficiency anaemia";"A11AA01";;"Added"
"multiple micronutrient supplement";"Other medicines administered to the mother";"Tablet containing: 
Vit A: 800 mcg retinol activity equivalent
Vit C: 70 mg
Vit D: 5 mcg (200 IU)
Vit E: 10 mg alpha tocopherol equivalent
Vit B1: 1.4 mg
Vit B2: 1.4 mg
Vit B3: 18 mg niacin equivalent
Vit B6: 1.9 mg
Folic acid: 400 mcg
Vit B12: 2.6 mcg
Iron: 30 mg
Iodine: 150 mcg
Zinc: 15 mg
Selenium: 65 mcg
Copper: 2 mg";"Maternal care for other specified conditions predominantly related to pregnancy";"A11AA01";;"Added"
"mumps vaccine";"Recommendations for immunization programmes with certain characteristics";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against mumps alone";"J07BE01";;"Added"
"mupirocin";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Cream: 2% (as mupirocin calcium)
Local > Topical > Ointment: 2%";"Superficial bacterial folliculitis";"D06AX09";;"Added"
"mupirocin";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Cream: 2% (as mupirocin calcium)
Local > Topical > Ointment: 2%";"Impetigo";"D06AX09";;"Added"
"nadroparin";"Medicines affecting coagulation";;"Acute ischaemic heart disease";;;"Added"
"nadroparin";"Medicines affecting coagulation";;"Venous thromboembolism";;;"Added"
"nalidixic acid";"Anti-infective medicines";"Oral > Solid: 250 mg; 500 mg";"Shigella resistant to unspecified antibiotic";"J01MB02";;"Removed"
"naloxone";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)";"Unintentional exposure to or harmful effects of opioids or related analgesics";"V03AB15";;"Added"
"natamycin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Suspension: 5% eye drops";"Infectious keratitis";"S01AA10";;"Added"
"nelfinavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 250 mg (as mesilate)
Oral > Other: 50 mg per  g oral powder";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE04";;"Removed"
"neostigmine";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Oral > Solid: 15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)";"Myasthenia gravis";"N07AA01";;"Added"
"neostigmine";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Oral > Solid: 15 mg (neostigmine bromide)
Parenteral > General injections > unspecified: 0.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per  mL in 1 mL ampoule (neostigmine metilsulfate)";"Anticholinesterase reversible";"N07AA01";;"Added"
"netilmicin";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"netilmicin";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"nevirapine";"Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors";"Oral > Liquid: 50 mg per 5 mL oral solution
Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AG01";;"Added"
"niclosamide";"Intestinal anthelminthics";"Oral > Solid: 500 mg tablet (chewable)";"Hymenolepiasis";"P02DA01";;"Added"
"niclosamide";"Intestinal anthelminthics";"Oral > Solid: 500 mg tablet (chewable)";"Diphyllobothriasis";"P02DA01";;"Added"
"niclosamide";"Intestinal anthelminthics";"Oral > Solid: 500 mg tablet (chewable)";"Taeniasis due to Taenia saginata";"P02DA01";;"Added"
"niclosamide";"Intestinal anthelminthics";"Oral > Solid: 500 mg tablet (chewable)";"Taeniasis due to Taenia solium";"P02DA01";;"Added"
"nicotinamide";"Vitamins and minerals";"Oral > Solid: 50 mg";"Pellagra";"A11HA01";;"Added"
"nifedipine";"Antioxytocics (tocolytics)";"Oral > Solid: 10 mg (immediate-release)";"Preterm labour without delivery";"C08CA05";;"Added"
"nifedipine";"Antianginal medicines";"Oral > Solid: 10 mg";"Angina pectoris";"C08CA05";;"Removed"
"nifedipine";"Antihypertensive medicines";"Oral > Solid: 10 mg tablet; sustained-release formulations";"Essential hypertension";"C08CA05";;"Removed"
"nifurtimox";"Medicines for the treatment of 2nd stage African trypanosomiasis";"Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)";"African trypanosomiasis";"P01CC01";;"Added"
"nifurtimox";"American trypanosomiasis";"Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)";"Chagas disease";"P01CC01";;"Added"
"nilotinib";"Targeted therapies";"Oral > Solid: 150 mg capsule; 200 mg capsule";"Chronic myeloid leukaemia, not elsewhere classified";"L01EA03";;"Added"
"nilutamide";"Hormones and antihormones";;"Malignant neoplasms of prostate";;;"Added"
"nitrous oxide";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation: ";"Anaesthetics and therapeutic gases";"N01AX13";;"Added"
"nivolumab";"Immunomodulators";"Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion";"Other specified malignant neoplasms of bronchus or lung";"L01FF01";;"Removed"
"nivolumab";"Immunomodulators";"Parenteral > General injections > IV: 10 mg per  mL concentrate solution for infusion";"Melanoma of skin";"L01FF01";;"Added"
"norethisterone";"Oral hormonal contraceptives";"Oral > Solid: 350 µg";"Contact with health services for contraceptive management";"G03AC01";;"Removed"
"norethisterone";"Progestogens";"Oral > Solid: 5 mg
";"Excessive menstruation with irregular cycle";"G03DC02";;"Removed"
"norethisterone";"Progestogens";"Oral > Solid: 5 mg
";"Excessive menstruation with irregular cycle";;;"Added"
"norethisterone enantate";"Injectable hormonal contraceptives";"Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule oily solution";"Contact with health services for reasons associated with reproduction";"G03AC01";;"Added"
"normal immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution";"Primary immunodeficiencies";;;"Added"
"normal immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution";"Mucocutaneous lymph node syndrome";;;"Added"
"normal immunoglobulin";"Human immunoglobulins";"Parenteral > General injections > IV: 5% protein solution; 10% protein solution
Parenteral > General injections > IM: 16% protein solution
Parenteral > General injections > SC: 15% protein solution; 16% protein solution";"Langerhans cell histiocytosis";"J06BA02";;"Added"
"nystatin";"Antifungal medicines";"Oral > Liquid: 100000 IU per  mL
Local > Topical > Other: 100000 IU pessary
Oral > Solid > dosage form: 500000 IU
Oral > Solid > lozenge: 100000 IU";"Candidosis";"A07AA02";;"Added"
"ocrelizumab";"Medicines for multiple sclerosis";"Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial
Parenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution";"Relapsing-remitting multiple sclerosis";"L03AX13";;"Removed"
"ocrelizumab";"Medicines for multiple sclerosis";"Parenteral > General injections > IV: 30 mg per  mL in 10 mL vial
Parenteral > General injections > IV: 30 mg per  mL in 10 vial concentrate for solution";"Multiple sclerosis";"L04AA36";;"Removed"
"ofloxacin";"Antituberculosis medicines";"Oral > Solid: 200 mg; 400 mg";"Multi-drug resistant Mycobacterium tuberculosis";"J01MA01";;"Removed"
"ofloxacin";"Ear, nose and throat medicines [c]";;"Infectious diseases of external ear";;;"Added"
"ofloxacin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 0.3%";"Other specified conjunctivitis";"S01AE01";;"Added"
"ofloxacin";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 0.3%";"Infectious keratitis";"S01AE01";;"Added"
"omadacycline";"Reserve group antibiotics";"Parenteral > General injections > IV: 100 mg lyophilized powder for injection
Oral > Solid: 300 mg";"Methicillin resistant Staphylococcus aureus";"J01AA15";;"Removed"
"ombitasvir + paritaprevir + ritonavir";"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations";"Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet";"Chronic hepatitis C";"J05AP53";;"Removed"
"omeprazole";"Antiulcer medicines";"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial";"Peptic ulcer, site unspecified";"A02BC01";;"Added"
"omeprazole";"Antiulcer medicines";"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial";"Gastro-oesophageal reflux disease";"A02BC01";;"Added"
"omeprazole";"Antiulcer medicines";"Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
Oral > Solid: 10 mg; 20 mg; 40 mg
Parenteral > General injections > IV: 40 mg in vial";"Gastrointestinal bleeding";"A02BC01";;"Added"
"ondansetron";"Medicines for other common symptoms in palliative care";"Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)
Oral > Liquid: 4 mg per 5 mL (ondansetron base)
Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)";"Palliative care";"A04AA01";;"Added"
"ondansetron";"Antiemetic medicines";"Parenteral > General injections > IV: 2 mg per  mL in 2 mL ampoule (ondansetron base, as hydrochloride)
Oral > Liquid: 4 mg per 5 mL (ondansetron base)
Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)";"Nausea or vomiting";"A04AA01";;"Added"
"oral rehydration salts";"Oral rehydration";"Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L";"Diarrhoea";"A07CA";;"Added"
"oral rehydration salts";"Solutions correcting water, electrolyte and acid-base disturbances > Oral";"Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L";"Other specified disorders of fluid, electrolyte or acid-base balance";"A07CA";;"Added"
"oral rehydration salts - zinc sulfate";"Medicines used in diarrhoea";"Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)";"Diarrhoea";"A07CA";;"Added"
"oseltamivir";"Other antivirals";"Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)";"Influenza due to identified seasonal influenza virus";"J05AH02";;"Added"
"oxaliplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial";"Malignant neoplasm metastasis in large intestine";"L01XA03";;"Added"
"oxaliplatin";"Cytotoxic medicines";"Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial";"Malignant neoplasms of colon";"L01XA03";;"Added"
"oxamniquine";"Antischistosomals and other antitrematode medicines";"Oral > Liquid: 250 mg per 5 mL
Oral > Solid: 250 mg capsule";"Schistosomiasis due to Schistosoma mansoni";"P02BA02";;"Added"
"oxazolindinones";"Reserve group antibiotics";".";"Other specified bacterial diseases";;;"Removed"
"oxycodone";"Opioid analgesics";;"Pain";;;"Added"
"oxygen";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation: (medical gas)";"Anaesthetics and therapeutic gases";"V03AN01";;"Added"
"oxygen";"Medical gases";"Respiratory > Inhalation: ";"Respiratory failure as acute or chronic";"V03AN01";;"Added"
"oxytetracycline";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"oxytetracycline";"Ophthalmological preparations > Anti-infective agents";;"Infectious keratitis";;;"Added"
"oxytetracycline";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"oxytetracycline";"Ophthalmological preparations > Anti-infective agents";;"Trachoma";;;"Added"
"oxytocin";"Uterotonics";"Parenteral > General injections > unspecified: 10 IU per  mL";"Postpartum haemorrhage";"H01BB02";;"Added"
"p-aminosalicylate sodium";"Antituberculosis medicines";"Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)";"Multi-drug resistant Mycobacterium tuberculosis";"J04AA01";;"Added"
"p-aminosalicylic acid";"Antituberculosis medicines";"Oral > Solid: 4 g granules in sachet";"Multi-drug resistant Mycobacterium tuberculosis";"J04AA01";;"Removed"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Other specified malignant neoplasms of the ovary";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Other specified malignant neoplasms of bronchus or lung";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Malignant neoplasms of nasopharynx";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Kaposi sarcoma of unspecified primary site";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Other specified malignant neoplasms of breast";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Other specified carcinomas of ovary";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Malignant neoplasms of breast";"L01CD01";;"Added"
"paclitaxel";"Cytotoxic medicines";"Parenteral > General injections > IV: 6 mg per  mL";"Malignant neoplasms of cervix uteri";"L01CD01";;"Added"
"palonosetron";"Medicines for other common symptoms in palliative care";;"Palliative care";;;"Added"
"palonosetron";"Antiemetic medicines";;"Nausea or vomiting";;;"Added"
"pancreatic enzymes";"Pancreatic enzymes";"Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.";"Enzyme intestinal";"A09AA02";;"Added"
"paracetamol (acetaminophen)";"Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)";"Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
Local > Rectal > Suppository: 100 mg; 250 mg
Oral > Solid > dispersible tablet: 100 mg; 250 mg
Oral > Solid > tablet: 250 mg; 325 mg; 500 mg";"Pain";"N02BE01";;"Added"
"paracetamol (acetaminophen)";"Antimigraine medicines > For treatment of acute attack";"Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
Local > Rectal > Suppository: 250 mg
Oral > Solid > dispersible tablet: 100 mg; 250 mg
Oral > Solid > tablet: 250 mg; 325 mg; 500 mg";"Migraine";"N02BE01";;"Added"
"paromomycin";"Antileishmaniasis medicines";"Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)";"Visceral leishmaniasis";"A07AA06";;"Added"
"paromomycin";"Antiamoebic and antigiardiasis medicines";"Oral > Liquid: 125 mg per 5 mL as sulfate
Oral > Solid: 250 mg as sulfate";"Amoebiasis";"A07AA06";;"Removed"
"pegaspargase";"Cytotoxic medicines";"Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection";"Lymphoid leukaemia, not elsewhere classified";"L01XX24";;"Added"
"pegylated interferon alfa (2a)";"Medicines for hepatitis C > Other antivirals for hepatitis C";"Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe";"Chronic hepatitis C";"L03AB11";;"Removed"
"pegylated interferon alfa (2b)";"Medicines for hepatitis C > Other antivirals for hepatitis C";"Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe";"Chronic hepatitis C";"L03AB10";;"Removed"
"pembrolizumab";"Immunomodulators";;"Melanoma of skin";;;"Added"
"penicillamine";"Antidotes and other substances used in poisonings > Specific";"Oral > Solid: 250 mg";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"M01CC01";;"Added"
"penicillamine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 250 mg";"Rheumatoid arthritis, serology unspecified";"M01CC01";;"Added"
"pentamidine";"Antileishmaniasis medicines";"Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)";"Visceral leishmaniasis";"P01CX01";;"Removed"
"pentamidine";"Antipneumocystosis and antitoxoplasmosis medicines";"Oral > Solid: 200 mg tablet; 300 mg tablet";"Pneumocystosis";"P01CX01";;"Added"
"pentamidine";"Medicines for the treatment of 1st stage African trypanosomiasis";"Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection";"African trypanosomiasis";"P01CX01";;"Added"
"permethrin";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%";"Pediculosis corporis";"P03AC04";;"Added"
"permethrin";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%";"Pediculosis capitis";"P03AC04";;"Added"
"permethrin";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Lotion: 1%
Local > Topical > Cream: 5%";"Scabies";"P03AC04";;"Added"
"pertussis vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against pertussis alone";"J07AJ02";;"Added"
"pertuzumab";"Targeted therapies";"Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution";"Carcinoma of breast, specialised type";"L01FD02";;"Removed"
"phenobarbital";"Antiseizure medicines";"Oral > Liquid: 15 mg per 5 mL
Oral > Solid: 15 to 100 mg
Parenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)";"Epilepsy or seizures";"N03AA02";;"Added"
"phenobarbital";"Antiseizure medicines";"Oral > Liquid: 15 mg per 5 mL
Oral > Solid: 15 to 100 mg
Parenteral > General injections > IV: 200 mg per  mL (phenobarbital sodium); 30 mg per  mL (phenobarbital sodium); 60 mg per  mL (phenobarbital sodium)";"Status epilepticus";"N03AA02";;"Added"
"phenoxymethylpenicillin";"Access group antibiotics";"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)";"Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)";"J01CE02";;"Added"
"phenoxymethylpenicillin";"Access group antibiotics";"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)";"Periapical abscess without sinus";"J01CE02";;"Added"
"phenoxymethylpenicillin";"Access group antibiotics";"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)";"Acute pharyngitis";"J01CE02";;"Added"
"phenoxymethylpenicillin";"Access group antibiotics";"Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
Oral > Solid: 250 mg (as potassium salt) tablet
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)";"Bacterial infection of unspecified site";"J01CE02";;"Removed"
"phenytoin";"Antiseizure medicines";"Oral > Liquid: 30 mg per 5 mL (phenytoin)
Parenteral > General injections > unspecified: 50 mg per  mL in vial (phenytoin sodium)
Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
Oral > Solid > dosage form: 50 mg (phenytoin sodium); 25 mg (phenytoin sodium); 100 mg (phenytoin sodium)";"Epilepsy or seizures";"N03AB02";;"Added"
"phytomenadione";"Medicines affecting coagulation";"Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule
Oral > Solid: 10 mg tablet";"Haemorrhagic disorder due to other specified circulating anticoagulants";"B02BA01";;"Added"
"phytomenadione";"Medicines affecting coagulation";"Parenteral > General injections > IV: 10 mg per  mL in ampoule; 1 mg per  mL in ampoule
Oral > Solid: 10 mg tablet";"Haemorrhagic or haematological disorders of fetus or newborn";"B02BA01";;"Added"
"pilocarpine";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)";"Acute angle closure with pupillary block";"S01EB01";;"Added"
"pilocarpine";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)";"Ocular hypertension";"S01EB01";;"Added"
"pilocarpine";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)";"Primary open-angle glaucoma";"S01EB01";;"Added"
"piperacillin + tazobactam";"Watch group antibiotics";"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection";"Other specified pneumonia (Hospital-acquired pneumonia)";"J01CR05";;"Added"
"piperacillin + tazobactam";"Watch group antibiotics";"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection";"Peritonitis (severe)";"J01CR05";;"Added"
"piperacillin + tazobactam";"Watch group antibiotics";"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection";"Neutropenia (high-risk)";"J01CR05";;"Added"
"piperacillin + tazobactam";"Watch group antibiotics";"Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection";"Peritoneal abscess (severe)";"J01CR05";;"Added"
"platelets";"Blood and blood components";"Parenteral > General injections > IV: ";"Blood transfusion without reported diagnosis";"B05AX02";;"Added"
"plazomicin";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)";"Carbapenem resistant Acinetobacter baumannii";"J01GB14";;"Added"
"plazomicin";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)";"Carbapenem-resistant Pseudomonas aeruginosa";"J01GB14";;"Added"
"plazomicin";"Reserve group antibiotics";"Parenteral > General injections > IV: 500 mg per 10 mL (Injection)";"Carbapenem resistant Enterobacterales";"J01GB14";;"Added"
"pneumococcal vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against single bacterial diseases";"J07AL01";;"Added"
"podophyllotoxin";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";;"Anogenital warts";;;"Added"
"podophyllotoxin";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";;"Plantar warts";;;"Added"
"podophyllum resin";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 10 to 25%";"Anogenital warts";"D06BB04";;"Added"
"podophyllum resin";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 10 to 25%";"Plantar warts";"D06BB04";;"Added"
"poliomyelitis vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against poliomyelitis";"J07BF01, J07BF02, J07BF03, J07BF04";;"Added"
"polygeline";"Plasma substitutes";"Parenteral > General injections > IV: 3.5% injectable solution
Parenteral > General injections > IV: 3.5% in solution";"Hypovolaemia";;;"Added"
"polygeline";"Plasma substitutes";"Parenteral > General injections > IV: 3.5% injectable solution
Parenteral > General injections > IV: 3.5% in solution";"Hypovolaemia";;;"Removed"
"polymyxins";"Reserve group antibiotics";".";"Other specified bacterial diseases";;;"Removed"
"potassium chloride";"Solutions correcting water, electrolyte and acid-base disturbances > Oral";"Oral > Liquid: powder for solution";"Hypokalaemia";"A12BA01";;"Added"
"potassium chloride";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)";"Hypokalaemia";"B05XA01";;"Added"
"potassium ferric hexacyanoferrate";"Antidotes and other substances used in poisonings > Specific";"Oral > Solid: Powder for oral administration";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB31";;"Added"
"potassium iodide";"Antifungal medicines";"Local > Topical > Solution: Saturated solution";"Sporotrichosis";;;"Added"
"potassium iodide";"Thyroid hormones and antithyroid medicines";"Oral > Solid: 60 mg";"Thyrotoxicosis";"V03AB21";;"Added"
"potassium permanganate";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Solution: aqueous solution: 1:10 000";"Tropical phagedaenic ulcer";"D08AX06";;"Added"
"potassium permanganate";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Solution: aqueous solution: 1:10 000";"Pemphigus";"D08AX06";;"Added"
"potassium permanganate";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Solution: aqueous solution: 1:10 000";"Other specified pyogenic bacterial infection of skin and subcutaneous tissue";"D08AX06";;"Added"
"potassium permanganate";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Solution: aqueous solution: 1:10 000";"Impetigo";"D08AX06";;"Added"
"povidone iodine";"Antiseptics";"Local > Topical > Solution: 10% (equivalent to 1% available iodine)";"Povidone iodine";"D08AG02";;"Added"
"pralidoxime";"Antidotes and other substances used in poisonings > Specific";".";"Exposure to or harmful effects of undetermined intent of pesticides";"V03AB04";;"Removed"
"pramipexole";"Antiseizure medicines";"Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release";"Parkinson disease";"N04BC05";;"Removed"
"pravastatin";"Lipid-lowering agents";;"Mixed hyperlipidaemia";;;"Added"
"pravastatin";"Lipid-lowering agents";;"Coronary atherosclerosis";;;"Added"
"praziquantel";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Paragonimiasis";"P02BA01";;"Added"
"praziquantel";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Clonorchiasis";"P02BA01";;"Added"
"praziquantel";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Opisthorchiasis";"P02BA01";;"Added"
"praziquantel";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Schistosomiasis";"P02BA01";;"Added"
"praziquantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Taeniasis due to Taenia saginata";"P02BA01";;"Added"
"praziquantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Taeniasis due to Taenia solium";"P02BA01";;"Added"
"praziquantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Diphyllobothriasis";"P02BA01";;"Added"
"praziquantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Hymenolepiasis";"P02BA01";;"Added"
"praziquantel";"Cysticidal medicines";"Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg";"Cysticercosis of central nervous system";"P02BA01";;"Added"
"precipitated sulfur";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Ointment: ";"Pthiriasis";;;"Added"
"precipitated sulfur";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Ointment: ";"Pediculosis corporis";;;"Added"
"precipitated sulfur";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Ointment: ";"Pediculosis capitis";;;"Added"
"precipitated sulfur";"Dermatological medicines > Scabicides and pediculicides";"Local > Topical > Ointment: ";"Scabies";;;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"H02AB06";;"Removed"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Plasma cell myeloma";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Follicular lymphoma";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Lymphoid leukaemia, not elsewhere classified";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Malignant neoplasms of prostate";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Hodgkin lymphoma";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Diffuse large B-cell lymphomas";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Burkitt lymphoma including Burkitt leukaemia";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Anaplastic large cell lymphoma, ALK-negative";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Anaplastic large cell lymphoma, ALK-positive";"H02AB06";;"Added"
"prednisolone";"Hormones and antihormones";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Langerhans cell histiocytosis";"H02AB06";;"Added"
"prednisolone";"Anti-inflammatory medicines";"Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)";"Crohn disease site";;;"Added"
"prednisolone";"Anti-inflammatory medicines";"Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)";"Crohn disease site";"A07EA01";;"Added"
"prednisolone";"Anti-inflammatory medicines";"Local > Rectal > Retention enema: 
Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)";"Ulcerative colitis";"A07EA01";;"Added"
"prednisolone";"Antiallergics and medicines used in anaphylaxis";"Oral > Liquid: 5 mg per  mL
Oral > Solid: 5 mg; 25 mg";"Allergic or hypersensitivity conditions of unspecified type";"H02AB06";;"Added"
"prednisolone";"Ophthalmological preparations > Anti-inflammatory agents";"Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)";"Scleritis";"S01BA04";;"Added"
"prednisolone";"Ophthalmological preparations > Anti-inflammatory agents";"Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)";"Anterior uveitis";"S01BA04";;"Added"
"prednisone";"Hormones and antihormones";;"Plasma cell myeloma";;;"Added"
"prednisone";"Hormones and antihormones";;"Follicular lymphoma";;;"Added"
"prednisone";"Hormones and antihormones";;"Lymphoid leukaemia, not elsewhere classified";;;"Added"
"prednisone";"Hormones and antihormones";;"Malignant neoplasms of prostate";;;"Added"
"prednisone";"Hormones and antihormones";;"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";;;"Added"
"prednisone";"Hormones and antihormones";;"Hodgkin lymphoma";;;"Added"
"prednisone";"Hormones and antihormones";;"Diffuse large B-cell lymphomas";;;"Added"
"prednisone";"Hormones and antihormones";;"Anaplastic large cell lymphoma, ALK-negative";;;"Added"
"prednisone";"Hormones and antihormones";;"Anaplastic large cell lymphoma, ALK-positive";;;"Added"
"prednisone";"Hormones and antihormones";;"Langerhans cell histiocytosis";;;"Added"
"prednisone";"Antiallergics and medicines used in anaphylaxis";;"Allergic or hypersensitivity conditions of unspecified type";;;"Added"
"pretomanid";"Antituberculosis medicines";"Oral > Solid > tablet: 200 mg";"Multi-drug resistant Mycobacterium tuberculosis";"J04AK08";;"Added"
"primaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)";"Malaria due to Plasmodium ovale";"P01BA03";;"Added"
"primaquine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)";"Malaria due to Plasmodium vivax";"P01BA03";;"Added"
"probenecid";"Medicines used to treat gout";"Oral > Solid: 500 mg";"Gout";"M04AB01";;"Removed"
"procainamide";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule (hydrochloride)
Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)";"Cardiac arrhythmia";"C01BA02";;"Removed"
"procaine benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection";"Congenital syphilis [children]";"J01CE09";;"Added"
"procaine benzylpenicillin";"Access group antibiotics";"Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection";"Syphilis";"J01CE09";;"Added"
"procarbazine";"Cytotoxic medicines";"Oral > Solid: 50 mg (as hydrochloride)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01XB01";;"Removed"
"procarbazine";"Cytotoxic medicines";"Oral > Solid: 50 mg (as hydrochloride)";"Hodgkin lymphoma";"L01XB01";;"Added"
"progesterone vaginal ring";"Intravaginal contraceptives";"Local > Vaginal > vaginal ring: 2.074 g micronized progesterone";"Contact with health services for contraceptive management";"G03DA04";;"Added"
"proguanil";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 100 mg tablet (hydrochloride)";"Malaria due to Plasmodium falciparum";"P01BB01";;"Added"
"promethazine";"Antiemetic medicines";"Oral > Liquid: 5 mg per 5 mL (hydrochloride)
Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule";"Nausea or vomiting";"R06AD02";;"Removed"
"propanol";"Antiseptics";;"Denatured alcohol";;;"Added"
"propofol";"General anaesthetics and oxygen > Injectable medicines";"Parenteral > General injections > IV: 10 mg per  mL; 20 mg per  mL";"Anaesthetics and therapeutic gases";"N01AX10";;"Added"
"propranolol";"Antihypertensive medicines";"Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)";"Essential hypertension";"C07AA05";;"Removed"
"propranolol";"Antianginal medicines";"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)";"Angina pectoris";"C07AA05";;"Removed"
"propranolol";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)
Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)";"Cardiac arrhythmia";"C07AA05";;"Removed"
"propranolol";"Antimigraine medicines > For prophylaxis";"Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)";"Migraine";"C07AA05";;"Added"
"propylthiouracil";"Thyroid hormones and antithyroid medicines";"Oral > Solid: 50 mg";"Thyrotoxicosis";"H03BA02";;"Added"
"prostaglandin E1";"Medicines administered to the neonate [c]";"Parenteral > General injections > IV: 0.5 mg per  mL in alcohol";"Other specified congenital anomaly of great arteries including arterial duct";"C01EA01";;"Added"
"prostaglandin E2";"Medicines administered to the neonate [c]";"Parenteral > General injections > IV: 1 mg per  mL";"Other specified congenital anomaly of great arteries including arterial duct";;;"Added"
"prostaglandin E2";"Medicines administered to the neonate [c]";"Parenteral > General injections > IV: 1 mg per  mL";"Other specified congenital anomaly of great arteries including arterial duct";"G02AD02";;"Removed"
"protamine sulfate";"Medicines affecting coagulation";"Parenteral > General injections > IV: 10 mg per  mL in 5 mL ampoule";"Haemorrhagic disorder due to other specified circulating anticoagulants";"V03AB14";;"Added"
"protionamide";"Antituberculosis medicines";;"Multi-drug resistant Mycobacterium tuberculosis";;;"Added"
"pyrantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)";"Ascariasis";"P02CC01";;"Added"
"pyrantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)";"Enterobiasis";"P02CC01";;"Added"
"pyrantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)";"Trichuriasis";"P02CC01";;"Added"
"pyrantel";"Intestinal anthelminthics";"Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)";"Hookworm diseases";"P02CC01";;"Added"
"pyrazinamide";"Antituberculosis medicines";"Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg";"Tuberculosis";"J04AK01";;"Added"
"pyridostigmine";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
Oral > Solid: 60 mg (pyridostigmine bromide)";"Myasthenia gravis";"N07AA02";;"Added"
"pyridoxine";"Vitamins and minerals";"Oral > Solid: 25 mg (hydrochloride)";"Vitamin B6 deficiency";"A11HA02";;"Added"
"pyridoxine";"Vitamins and minerals";"Oral > Solid: 25 mg (hydrochloride)";"Sideroblastic anaemia";"A11HA02";;"Added"
"pyridoxine";"Vitamins and minerals";"Oral > Solid: 25 mg (hydrochloride)";"Other specified polyneuropathy";"A11HA02";;"Added"
"pyrimethamine";"Antipneumocystosis and antitoxoplasmosis medicines";"Oral > Solid: 25 mg";"Toxoplasmosis";"P01BD01";;"Added"
"quinidine";"Antiarrhythmic medicines";"Oral > Solid: 200 mg (sulfate)";"Cardiac arrhythmia";"C01BA01";;"Removed"
"quinine";"Antimalarial medicines > For curative treatment";"Parenteral > General injections > IV: 300 mg per  mL in 2 mL ampoule (quinine hydrochloride)
Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)";"Malaria due to Plasmodium falciparum";"P01BC01";;"Added"
"rabies vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against rabies";"J07BG01";;"Added"
"raltegravir";"Antiretrovirals > Integrase inhibitors";"Oral > Liquid: 100 mg granules for oral suspension
Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AJ01";;"Added"
"ranibizumab";"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations";".";"Retinal venous occlusions";"S01LA04";;"Removed"
"ranibizumab";"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations";".";"Diabetic macular oedema";"S01LA04";;"Removed"
"ranibizumab";"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations";".";"Degenerative high myopia";"S01LA04";;"Removed"
"ranibizumab";"Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations";".";"Age related macular degeneration";"S01LA04";;"Removed"
"ranitidine";"Antiulcer medicines";"Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)";"Gastro-oesophageal reflux disease";"A02BA02";;"Added"
"ranitidine";"Antiulcer medicines";"Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
Oral > Solid: 150 mg (as hydrochloride)
Parenteral > General injections > unspecified: 25 mg per  mL in 2 mL ampoule (as hydrochloride)";"Peptic ulcer, site unspecified";"A02BA02";;"Added"
"rasburicase";"Supportive medicines";"Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution";"Tumour lysis syndrome";"V03AF07";;"Added"
"ravidasvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid > tablet: 200 mg";"Chronic hepatitis C";;;"Added"
"realgar-indigo naturalis formulation";"Cytotoxic medicines";"Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)";"Acute myeloid leukaemia with recurrent genetic abnormalities";;;"Added"
"red blood cells";"Blood and blood components";"Parenteral > General injections > IV: ";"Blood transfusion without reported diagnosis";"B05AX01";;"Added"
"retinol";"Vitamins and minerals";"Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
Oral > Liquid: 100000 IU per  mL (as palmitate) oral oily solution in multidose dispenser
Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule";"Vitamin A deficiency";"A11CA01";;"Added"
"ribavirin";"Other antivirals";"Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg";"Viral haemorrhagic fever, not elsewhere classified";"J05AB04";;"Added"
"ribavirin";"Medicines for hepatitis C > Other antivirals for hepatitis C";"Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg";"Chronic hepatitis C";"J05AP01";;"Added"
"riboflavin";"Vitamins and minerals";"Oral > Solid: 5 mg";"Vitamin B2 deficiency";"A11HA04";;"Added"
"rifabutin";"Antituberculosis medicines";"Oral > Solid: 150 mg";"Tuberculosis";"J04AB04";;"Added"
"rifampicin";"Antituberculosis medicines";"Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg
Parenteral > General injections > IV: 600 mg in vial powder for injection";"Tuberculosis";"J04AB02";;"Added"
"rifampicin";"Antituberculosis medicines";"Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg
Parenteral > General injections > IV: 600 mg in vial powder for injection";"Other specified tuberculosis";"J04AB02";;"Removed"
"rifampicin";"Antileprosy medicines";"Oral > Liquid: 20 mg per  mL
Oral > Solid: 150 mg; 300 mg";"Leprosy";"J04AB02";;"Added"
"rifapentine";"Antituberculosis medicines";"Oral > Solid: 150 mg tablet; 300 mg tablet";"Tuberculosis";"J04AB05";;"Added"
"rifapentine";"Antituberculosis medicines";"Oral > Solid: 150 mg tablet; 300 mg tablet";"Latent tuberculosis";"J04AB05";;"Added"
"risdiplam";"Medicines for diseases of the nervous system";"Oral > Liquid: 0.75 mg per  mL powder for oral liquid";"Spinal muscular atrophy";"M09AX10";;"Removed"
"ritonavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE03";;"Added"
"rituximab";"Targeted therapies";"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial";"Follicular lymphoma";"L01FA01";;"Added"
"rituximab";"Targeted therapies";"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial";"Chronic lymphocytic leukaemia or small lymphocytic lymphoma";"L01FA01";;"Added"
"rituximab";"Targeted therapies";"Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial";"Diffuse large B-cell lymphomas";"L01FA01";;"Added"
"rituximab";"Medicines for multiple sclerosis";"Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial";"Multiple sclerosis";"L01FA01";;"Added"
"rivaroxaban";"Medicines affecting coagulation";;"Venous thromboembolism";;;"Added"
"rivaroxaban";"Medicines affecting coagulation";;"Other specified atrial fibrillation";;;"Added"
"ropinirole";"Antiseizure medicines";"Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release";"Parkinson disease";"N04BC04";;"Removed"
"rotavirus vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BH01, J07BH02";;"Added"
"rubella vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against rubella alone";"J07BJ01";;"Added"
"salbutamol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Parenteral > General injections > IV: 50 µg per  mL in 5 mL ampoule (as sulfate)
Respiratory > Inhalation > aerosol: 100 µg per  dose (as sulfate); 100 µg per  dose (as sulfate) metered-dose inhaler
Respiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers";"Chronic obstructive pulmonary disease";"R03AC02";;"Added"
"salbutamol";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Parenteral > General injections > IV: 50 µg per  mL in 5 mL ampoule (as sulfate)
Respiratory > Inhalation > aerosol: 100 µg per  dose (as sulfate); 100 µg per  dose (as sulfate) metered-dose inhaler
Respiratory > Inhalation > solution: 5 mg per  mL (as sulfate) for use in nebulizers";"Asthma";"R03AC02";;"Added"
"salicylic acid";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 5%";"Seborrhoeic dermatitis";"D01AE12";;"Added"
"salicylic acid";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 5%";"Psoriasis of unspecified type";"D01AE12";;"Added"
"salicylic acid";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Solution: 5%";"Ichthyoses";"D01AE12";;"Added"
"saquinavir";"Antiretrovirals > Protease inhibitors";"Oral > Solid: 200 mg; 500 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AE01";;"Removed"
"selenium sulfide";"Dermatological medicines > Antifungal medicines";"Local > Topical > Suspension: 2% detergent-based";"Seborrhoeic dermatitis";"D01AE13";;"Added"
"selenium sulfide";"Dermatological medicines > Antifungal medicines";"Local > Topical > Suspension: 2% detergent-based";"Pityriasis versicolor";"D01AE13";;"Added"
"senna";"Medicines for other common symptoms in palliative care";"Oral > Liquid: 7.5 mg per 5 mL oral liquid";"Palliative care";"A06AB06";;"Added"
"senna";"Laxatives";"Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)";"Constipation";"A06AB06";;"Added"
"sevoflurane";"General anaesthetics and oxygen > Inhalational medicines";"Respiratory > Inhalation > liquid: ";"Anaesthetics and therapeutic gases";"N01AB08";;"Added"
"silver diamine fluoride";"Dental medicines and preparations";"Local > Dental > Solution: 38% w/v";"Dental caries";;;"Added"
"silver nitrate";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Solution (eye drops): 1%";"Neonatal conjunctivitis or dacryocystitis";"D08AL01";;"Removed"
"silver sulfadiazine";"Dermatological medicines > Anti-infective medicines";"Local > Topical > Cream: 1%";"Burns";"D06BA01";;"Added"
"simeprevir";"Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations";"Oral > Solid: 150 mg";"Chronic hepatitis C";"J05AP05";;"Removed"
"simvastatin";"Lipid-lowering agents";"Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg";"Mixed hyperlipidaemia";"C10AA01";;"Added"
"simvastatin";"Lipid-lowering agents";"Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg";"Coronary atherosclerosis";"C10AA01";;"Added"
"simvastatin";"Medicines for endocrine disorders";"Oral > Solid: 20 mg";"Polycystic ovary syndrome";"C10AA01";;"Removed"
"smallpox vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BX01";;"Removed"
"snake antivenom";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";".";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"J06AA03";;"Removed"
"sodium calcium edetate";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 200 mg per  mL in 5 mL ampoule";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB03";;"Added"
"sodium chloride";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)";"Other specified disorders of fluid, electrolyte or acid-base balance";"B05XA03";;"Added"
"sodium hydrogen carbonate";"Solutions correcting water, electrolyte and acid-base disturbances > Parenteral";"Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na+ 167 mmol/L and HCO3- 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L and HCO3- 1000 mmol/L)";"Acidosis";"B05XA02";;"Added"
"sodium nitrite";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 30 mg per  mL in 10 mL ampoule";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB08";;"Added"
"sodium nitroprusside";"Antihypertensive medicines";"Parenteral > General injections > IV: 50 mg in ampoule powder for infusion";"Hypertensive crisis";"C02DD01";;"Added"
"sodium stibogluconate";"Antileishmaniasis medicines";"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial";"Visceral leishmaniasis";"P01CB02";;"Added"
"sodium stibogluconate";"Antileishmaniasis medicines";"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial";"Mucocutaneous leishmaniasis";"P01CB02";;"Added"
"sodium stibogluconate";"Antileishmaniasis medicines";"Parenteral > General injections > unspecified: 100 mg per  mL in 30 mL vial";"Cutaneous leishmaniasis";"P01CB02";;"Added"
"sodium thiosulfate";"Dermatological medicines > Antifungal medicines";"Local > Topical > Solution: 15%";"Pityriasis versicolor";"V03AB06";;"Added"
"sodium thiosulfate";"Antidotes and other substances used in poisonings > Specific";"Parenteral > General injections > IV: 250 mg per  mL in 50 mL ampoule";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";"V03AB06";;"Added"
"sofosbuvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid: 400 mg; 200 mg";"Chronic hepatitis C";"J05AP08";;"Added"
"sofosbuvir + velpatasvir";"Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations";"Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet";"Chronic hepatitis C";"J05AP55";;"Added"
"spectinomycin";"Access group antibiotics";"Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection";"Gonococcal infection";"J01XX04";;"Added"
"spectinomycin";"Access group antibiotics";"Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection";"Bacterial infection of unspecified site";"J01XX04";;"Removed"
"spironolactone";"Medicines used in heart failure";"Oral > Solid: 25 mg";"Heart failure";"C03DA01";;"Added"
"spironolactone";"Diuretics";"Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
Oral > Solid: 25 mg";"Oedema";"C03DA01";;"Added"
"spironolactone";"Diuretics";"Oral > Liquid: 10 mg per 5 mL; 25 mg per 5 mL; 5 mg per 5 mL
Oral > Solid: 25 mg";"Ascites";"C03DA01";;"Added"
"stavudine";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Liquid: 5 mg per 5 mL powder for oral solution
Oral > Solid: 15 mg; 20 mg; 30 mg";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF04";;"Removed"
"streptokinase";"Thrombolytic medicines";"Parenteral > General injections > IV: 1.5 million IU in vial powder for injection";"Acute myocardial infarction";"B01AD01";;"Added"
"streptomycin (injection)";"Antituberculosis medicines";"Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial";"Multi-drug resistant Mycobacterium tuberculosis";"J01GA01";;"Added"
"succimer";"Antidotes and other substances used in poisonings > Specific";"Oral > Solid: 100 mg";"Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified";;;"Added"
"sulfacetamide";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 10% (sodium salt)";"Other specified conjunctivitis";"S01AB04";;"Removed"
"sulfadiazine";"Antipneumocystosis and antitoxoplasmosis medicines";"Oral > Solid: 500 mg";"Toxoplasmosis";"J01EC02";;"Added"
"sulfadiazine";"Anti-infective medicines";"Oral > Solid: 500 mg
Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)";"Bacterial infection of unspecified site";"J01EC02";;"Removed"
"sulfadimidine";"Anti-infective medicines";"Oral > Liquid: 500 mg per 5 mL
Oral > Solid: 500 mg
Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)";"Bacterial infection of unspecified site";"J01EB03";;"Removed"
"sulfadoxine + pyrimethamine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 500 mg + 25 mg tablet";"Malaria due to Plasmodium falciparum";"P01BD51";;"Added"
"sulfadoxine + pyrimethamine";"Antimalarial medicines > For curative treatment";"Oral > Solid: 500 mg + 25 mg tablet";"Malaria due to Plasmodium vivax";"P01BD51";;"Added"
"sulfadoxine + pyrimethamine";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 500 mg + 25 mg tablet
Oral > Solid: 250 mg + 12.5 mg tablet";"Malaria due to Plasmodium falciparum";"P01BD51";;"Added"
"sulfadoxine + pyrimethamine";"Antimalarial medicines > For chemoprevention";"Oral > Solid: 500 mg + 25 mg tablet
Oral > Solid: 250 mg + 12.5 mg tablet";"Malaria";"P01BD51";;"Added"
"sulfamethoxazole + trimethoprim";"Access group antibiotics";"Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 10 mL ampoule; 80 mg + 16 mg per  mL in 5 mL ampoule
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet";"Bacterial infection of unspecified site";"J01EE01";;"Removed"
"sulfamethoxazole + trimethoprim";"Antipneumocystosis and antitoxoplasmosis medicines";"Parenteral > General injections > IV: 80 mg + 16 mg per  mL in 5 mL ampoule; 80 mg + 16 mg per  mL in 10 mL ampoule
Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid
Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet
Oral > Solid > dispersible tablet: 100 mg + 20 mg";"Pneumocystosis";"J01EE01";;"Added"
"sulfasalazine";"Disease-modifying anti-rheumatic drugs (DMARDs)";"Oral > Solid: 500 mg";"Rheumatoid arthritis, serology unspecified";"A07EC01";;"Added"
"sulfasalazine";"Anti-inflammatory medicines";"Oral > Solid: 500 mg
Local > Rectal > Suppository: 500 mg
Local > Rectal > Retention enema: ";"Crohn disease site";"A07EC01";;"Added"
"sulfasalazine";"Anti-inflammatory medicines";"Oral > Solid: 500 mg
Local > Rectal > Suppository: 500 mg
Local > Rectal > Retention enema: ";"Ulcerative colitis";"A07EC01";;"Added"
"sumatriptan";"Antimigraine medicines > For treatment of acute attack";"Oral > Solid: 50 mg";"Migraine";"N02CC01";;"Added"
"suramin sodium";"Antifilarials";"Parenteral > General injections > IV: 1 g in vial";"Filariasis";"P01CX02";;"Removed"
"suramin sodium";"Medicines for the treatment of 1st stage African trypanosomiasis";"Parenteral > General injections > IV: 1 g in vial";"African trypanosomiasis";"P01CX02";;"Added"
"surfactant";"Medicines administered to the neonate [c]";"Respiratory > Suspension: 80 mg per  mL for intratracheal instillation; 25 mg per  mL for intratracheal instillation";"Respiratory distress syndrome of newborn";"R07AA02";;"Added"
"suxamethonium";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 50 mg per  mL in 2 mL ampoule (suxamethonium chloride); powder for injection (suxamethonium chloride) in vial";"Muscle relaxants";"M03AB01";;"Added"
"tacalcitol";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";;"Psoriasis of unspecified type";;;"Added"
"tacrolimus";"Immunomodulators for non-malignant disease";"Parenteral > General injections > IV: 5 mg per  mL in 1 mL vial
Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)";"Failure or rejection of transplanted organs or tissues";"L04AD02";;"Added"
"tamoxifen";"Hormones and antihormones";"Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)";"Other specified malignant neoplasms of breast";"L02BA01";;"Added"
"tamoxifen";"Hormones and antihormones";"Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)";"Malignant neoplasms of breast";"L02BA01";;"Added"
"telmisartan + amlodipine";"Antihypertensive medicines";"Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg";"Essential hypertension";"C09DB04";;"Added"
"telmisartan + hydrochlorothiazide";"Antihypertensive medicines";"Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg";"Essential hypertension";"C09DA07";;"Added"
"tenofovir alafenamide";"Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Solid: 25 mg";"Chronic hepatitis B";"J05AF13";;"Removed"
"tenofovir disoproxil fumarate";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF07";;"Added"
"tenofovir disoproxil fumarate";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)";"Contact with or exposure to human immunodeficiency virus";"J05AF07";;"Added"
"tenofovir disoproxil fumarate";"Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)";"Chronic hepatitis B";"J05AF07";;"Added"
"terbinafine";"Dermatological medicines > Antifungal medicines";"Local > Topical > Cream: 1% terbinafine hydrochloride
Local > Topical > Ointment: 1% terbinafine hydrochloride";"Fungal infection of the skin";"D01AE15";;"Added"
"terbutaline";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Chronic obstructive pulmonary disease";;;"Added"
"terbutaline";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Asthma";;;"Added"
"terizidone";"Antituberculosis medicines";;"Multi-drug resistant Mycobacterium tuberculosis";;;"Added"
"testosterone";"Androgens";"Parenteral > General injections > IM: 200 mg per  mL in 1 mL ampoule (enantate)";"Testicular dysfunction or testosterone-related disorders";"G03BA03";;"Added"
"tetanus antitoxin";"Immunologicals > Sera, immunoglobulins and monoclonal antibodies";"Parenteral > General injections > IM: 50000 IU in vial";"Tetanus";"J06AA02";;"Removed"
"tetanus vaccine";"Recommendations for all immunization programmes";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against tetanus alone";"J07AM01";;"Added"
"tetracaine";"Ophthalmological preparations > Local anaesthetics";"Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride)";"Local anaesthetics";"S01HA03";;"Added"
"tetracycline";"Access group antibiotics";"Oral > Solid: 250 mg (hydrochloride)";"Bacterial infection of unspecified site";"J01AA07";;"Removed"
"tetracycline";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)";"Neonatal conjunctivitis or dacryocystitis";"S01AA09";;"Removed"
"tetracycline";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)";"Other specified conjunctivitis";"S01AA09";;"Added"
"tetracycline";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)";"Infectious keratitis";"S01AA09";;"Added"
"tetracycline";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)";"Infectious blepharitis";"S01AA09";;"Added"
"tetracycline";"Ophthalmological preparations > Anti-infective agents";"Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride)";"Trachoma";"S01AA09";;"Added"
"thalidomide";"Immunomodulators";"Oral > Solid: 50 mg";"Plasma cell myeloma";"L04AX02";;"Added"
"thiamine";"Vitamins and minerals";"Oral > Solid: 50 mg (hydrochloride)";"Vitamin B1 deficiency";"A11DA01";;"Added"
"thiopental";"General anaesthetics and oxygen > Injectable medicines";;"Anaesthetics and therapeutic gases";;;"Added"
"tick-borne encephalitis vaccine";"Recommendations for certain regions";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against arthropod-borne viral encephalitis";"J07BA01";;"Added"
"tigecycline";"Reserve group antibiotics";"Parenteral > General injections > IV: 50 mg in vial powder for injection";"Other specified bacterial diseases";"J01AA12";;"Removed"
"timolol";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)";"Primary open-angle glaucoma";"S01ED01";;"Added"
"timolol";"Ophthalmological preparations > Miotics and antiglaucoma medicines";"Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)";"Ocular hypertension";"S01ED01";;"Added"
"tinidazole";"Antiamoebic and antigiardiasis medicines";;"Amoebiasis";;;"Added"
"tioguanine";"Cytotoxic medicines";"Oral > Solid: 40 mg";"Lymphoid leukaemia, not elsewhere classified";"L01BB03";;"Added"
"tiotropium bromide";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";"Respiratory > Inhalation > dry powder: 18 µg capsule
Respiratory > Inhalation > solution: 1.25 µg per  actuation; 2.5 µg per  actuation";"Chronic obstructive pulmonary disease";"R03BB04";;"Added"
"tisagenlecleucel";"Antineoplastics and supportive medicines";;"Diffuse large B-cell lymphomas";;;"Removed"
"tislelizumab";"Immunomodulators";"Parenteral > General injections > IV: 100 mg per 10 mL";"Malignant neoplasms of urinary tract";"L01FF09";;"Removed"
"tislelizumab";"Immunomodulators";"Parenteral > General injections > IV: 100 mg per 10 mL";"Hodgkin lymphoma";"L01FF09";;"Removed"
"tobramycin";"Ophthalmological preparations > Anti-infective agents";;"Other specified conjunctivitis";;;"Added"
"tobramycin";"Ophthalmological preparations > Anti-infective agents";;"Infectious blepharitis";;;"Added"
"tolbutamide";"Oral hypoglycaemic agents";"Oral > Solid: 500 mg";"Type 2 diabetes mellitus";"A10BB03";;"Removed"
"torasemide";"Medicines used in heart failure";;"Heart failure";;;"Added"
"torasemide";"Diuretics";;"Anuria or oliguria";;;"Added"
"torasemide";"Diuretics";;"Oedema";;;"Added"
"tramadol";"Opioid analgesics";"Oral > Liquid: 100 mg per  mL (hydrochloride)
Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release
Parenteral > General injections > unspecified: 50 mg per  mL in 2 mL ampoule (hydrochloride)";"Chronic cancer pain";"N02AX02";;"Removed"
"trametinib";"Targeted therapies";"Oral > Solid: 0.5 mg; 2 mg";"Other specified melanoma of skin";"L01EE01";;"Removed"
"tranexamic acid";"Medicines affecting coagulation";"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule";"Haemorrhage, not elsewhere classified";"B02AA02";;"Added"
"tranexamic acid";"Other medicines administered to the mother";"Parenteral > General injections > IV: 100 mg per  mL in 10 mL ampoule";"Postpartum haemorrhage";"B02AA02";;"Added"
"trastuzumab";"Targeted therapies";"Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection";"Carcinoma of breast, specialised type";"L01FD01";;"Added"
"trastuzumab emtansine";"Targeted therapies";"Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection";"Carcinoma of breast, specialised type";"L01FD03";;"Removed"
"triclabendazole";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 250 mg (scored)";"Fascioliasis";"P02BX04";;"Added"
"triclabendazole";"Antischistosomals and other antitrematode medicines";"Oral > Solid > tablet: 250 mg (scored)";"Paragonimiasis";"P02BX04";;"Added"
"trihexyphenidyl";"Antiseizure medicines";"Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)";"Parkinson disease";"N04AA01";;"Removed"
"trihexyphenidyl";"Medicines for parkinsonism";;"Parkinson disease";;;"Added"
"trimethoprim";"Access group antibiotics";"Oral > Liquid: 50 mg per  mL
Oral > Solid: 100 mg; 200 mg";"Infectious cystitis";"J01EA01";;"Added"
"triptorelin";"Hormones and antihormones";;"Malignant neoplasms of breast";;;"Added"
"triptorelin";"Hormones and antihormones";;"Malignant neoplasms of prostate";;;"Added"
"tropicamide";"Diagnostic agents > Ophthalmic medicines";"Local > Ophthalmological > Solution (eye drops): 0.5%";"Cycloplegic drug";"S01FA06";;"Added"
"tropisetron";"Medicines for other common symptoms in palliative care";;"Palliative care";;;"Added"
"tropisetron";"Antiemetic medicines";;"Nausea or vomiting";;;"Added"
"tuberculin, purified protein derivative";"Immunologicals > Diagnostic agents";"Parenteral > Locoregional injections > Intradermal: ";"Mycobacterial diseases";"V04CF01";;"Added"
"tubocurarine";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 10 mg per  mL in 1.5 mL ampoule (tubocurarine chloride)";"Muscle relaxants";"M03AA02";;"Removed"
"typhoid vaccine";"Recommendations for some high-risk populations";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against typhoid-paratyphoid alone";"J07AP03";;"Added"
"ulipristal";"Oral hormonal contraceptives";"Oral > Solid: 30 mg tablet (ulipristal acetate)";"Contact with health services for postcoital contraception";"G03AD02";;"Added"
"umeclidinium";"Antiasthmatic and medicines for chronic obstructive pulmonary disease";;"Chronic obstructive pulmonary disease";;;"Added"
"urea";"Dermatological medicines > Medicines affecting skin differentiation and proliferation";"Local > Topical > Cream: 10%; 5%
Local > Topical > Ointment: 10%; 5%";"Xerosis cutis or asteatosis";"D02AE01";;"Added"
"valaciclovir";"Antiherpes medicines";;"Zoster";;;"Added"
"valaciclovir";"Antiherpes medicines";;"Varicella";;;"Added"
"valaciclovir";"Antiherpes medicines";;"Herpes simplex infections";;;"Added"
"valganciclovir";"Other antivirals";"Oral > Liquid: 50 mg per  mL powder for oral solution
Oral > Solid: 450 mg Tablet";"Cytomegaloviral retinitis";"J05AB14";;"Added"
"valproic acid (sodium valproate)";"Antiseizure medicines";"Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule";"Epilepsy or seizures";"N03AG01";;"Added"
"valproic acid (sodium valproate)";"Antiseizure medicines";"Oral > Liquid: 200 mg per 5 mL
Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)
Parenteral > General injections > IV: 100 mg per  mL in 4 mL ampoule; 100 mg per  mL in 10 mL ampoule; 100 mg per  mL in 3 mL ampoule";"Status epilepticus";"N03AG01";;"Added"
"valproic acid (sodium valproate)";"Medicines for bipolar disorders";"Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)";"Bipolar or related disorders";"N03AG01";;"Added"
"vancomycin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection";"Endophthalmitis";"J01XA01";"ceftazidime";"Added"
"vancomycin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection";"Endophthalmitis";"J01XA01";"ceftriaxone";"Added"
"vancomycin";"Watch group antibiotics";"Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection";"Methicillin resistant Staphylococcus aureus";"J01XA01";;"Removed"
"varenicline";"Medicines for nicotine use disorders";"Oral > Solid: 0.5 mg; 1 mg";"Nicotine dependence";"N07BA03";;"Added"
"varicella vaccine";"Recommendations for immunization programmes with certain characteristics";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BK01";;"Added"
"vecuronium";"Muscle relaxants (peripherally-acting) and cholinesterase inhibitors";"Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)";"Muscle relaxants";"M03AC03";;"Added"
"vemurafenib";"Targeted therapies";;"Other specified melanoma of skin";;;"Removed"
"verapamil";"Antiarrhythmic medicines";"Parenteral > General injections > IV: 2.5 mg per  mL in 2 mL ampoule (hydrochloride)
Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)";"Supraventricular tachyarrhythmia";"C08DA01";;"Added"
"verapamil";"Antianginal medicines";"Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)";"Angina pectoris";"C08DA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01CA01";;"Removed"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Other specified gliomas of brain";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Kaposi sarcoma of unspecified primary site";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Hodgkin lymphoma";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Other specified malignant neoplasms of the ovary";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Germ cell tumour of testis";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Anaplastic large cell lymphoma, ALK-negative";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Anaplastic large cell lymphoma, ALK-positive";"L01CA01";;"Added"
"vinblastine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)";"Langerhans cell histiocytosis";"L01CA01";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Unspecified malignant neoplasms of ill-defined or unspecified sites";"L01CA02";;"Removed"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Other specified gliomas of brain";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Malignant trophoblastic neoplasms of placenta";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Follicular lymphoma";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Kaposi sarcoma of unspecified primary site";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Rhabdomyosarcoma primary site";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Hodgkin lymphoma";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Diffuse large B-cell lymphomas";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Retinoblastoma";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Burkitt lymphoma including Burkitt leukaemia";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Malignant neoplasms of kidney, except renal pelvis";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Ewing sarcoma of bone and articular cartilage of unspecified sites";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Lymphoid leukaemia, not elsewhere classified";"L01CA02";;"Added"
"vincristine";"Cytotoxic medicines";"Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per  mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)";"Langerhans cell histiocytosis";"L01CA02";;"Added"
"vinorelbine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg";"Other specified malignant neoplasms of bronchus or lung";"L01CA04";;"Added"
"vinorelbine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg";"Other specified malignant neoplasms of breast";"L01CA04";;"Added"
"vinorelbine";"Cytotoxic medicines";"Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial
Parenteral > General injections > IV: 10 mg per  mL in 1 mL vial; 10 mg per  mL in 5 mL vial
Oral > Solid: 20 mg; 30 mg; 80 mg";"Rhabdomyosarcoma primary site";"L01CA04";;"Added"
"voriconazole";"Antifungal medicines";"Parenteral > General injections > IV: 200 mg in vial powder for injection
Oral > Liquid: 40 mg per  mL powder for oral liquid
Oral > Solid: 50 mg tablet; 200 mg tablet";"Chronic pulmonary aspergillosis";"J02AC03";;"Added"
"voriconazole";"Antifungal medicines";"Parenteral > General injections > IV: 200 mg in vial powder for injection
Oral > Liquid: 40 mg per  mL powder for oral liquid
Oral > Solid: 50 mg tablet; 200 mg tablet";"Invasive aspergillosis";"J02AC03";;"Added"
"warfarin";"Medicines affecting coagulation";"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)";"Other specified diseases of arteries or arterioles";"B01AA03";;"Added"
"warfarin";"Medicines affecting coagulation";"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)";"Cerebral ischaemic stroke due to embolic occlusion";"B01AA03";;"Added"
"warfarin";"Medicines affecting coagulation";"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)";"Venous thromboembolism";"B01AA03";;"Added"
"warfarin";"Medicines affecting coagulation";"Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt)";"Atrial fibrillation";"B01AA03";;"Added"
"water for injection";"Solutions correcting water, electrolyte and acid-base disturbances > Miscellaneous";"Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule";"Unspecified appropriateness of dosing or administration without injury or harm";;;"Added"
"whole blood";"Blood and blood components";"Parenteral > General injections > IV: ";"Blood transfusion without reported diagnosis";;;"Added"
"xylometazoline";"Ear, nose and throat medicines [c]";"Local > Nasal > Spray: 0.05% w/v equivalent to 0.5 mg per mL";"Nasal congestion";"R01AA07";;"Added"
"yellow fever vaccine";"Recommendations for certain regions";"All vaccines should comply with the WHO requirements for biological substances.";"Need for immunization against certain single viral diseases";"J07BL01";;"Added"
"zanubrutinib";"Targeted therapies";"Oral > Solid: 80 mg";"Mantle cell lymphoma";"L01EL03";;"Removed"
"zidovudine";"Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors";"Parenteral > General injections > IV: 10 mg per  mL in 20 mL vial solution for IV infusion injection
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 250 mg capsule; 300 mg tablet";"Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified";"J05AF01";;"Added"
"zinc sulfate";"Medicines for diarrhoea";"Oral > Solid: 20 mg";"Diarrhoea";"A12CB01";;"Added"
"zoledronic acid";"Supportive medicines";"Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle";"Malignant neoplasm metastasis in bone or bone marrow";"M05BA08";;"Added"
